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STELLING EN 
1 De effectiviteit van water-in-olie emulsies als vehike/ voor geinactiveerde 
vaccins kan niet alleen verklaard worden door dit type emulsie te be­
schrijven als een systeem, dat de afgifte van antigenen regu/eert. 
(dit proefschrift) 
2 Bio-imaging is een techniek die een absolute meerwaarde kan toevoegen 
aan vaccintechnologisch onderzoek, omdat het vee/ inzicht kan verschaffen 
in zowel fysisch chemische als biologische en immunologische aspecten 
van een vaccinformulering. (dit proefschrift) 
3 In vaccintechnologie zijn de fysisch chemische aspecten net zo belangrijk 
als de immunologische aspecten. Derhalve is een combinatie van deze 
disciplines gewenst om een gedegen studie te kunnen uitvoeren op vac­
cintechnologisch gebied. 
4 Er is in de immunologische wetenschap in het algemeen een gebrek aan 
vaccintechnologisch inzicht, wat voora/ blijkt uit verwaar/ozing van aan­
dacht voor samenstelling en bereiding van vaccins. Dit kan de reden zijn, 
waarom al decennia fang dezelfde traditionele vaccinformuleringen ge­
bruikt worden. 
S De beste wetenschappe/ijke onderzoeker heeft een integer karakter en 
streeft niet naar roem. De meest roemrijke wetenschapper hoeft dus niet 
de beste te zijn. 
6 Het gebrek aan maatschappe/ijke betrokkenheid in deze tijd heeft niets 
te maken met individua/isering, maar al/es met egoisme. 
7 Kinderen kunnen heel gemakkelijk kennis opnemen, die ze hun hele /even 
bijna niet meer verleren. Oat deze capaciteit gebruikt wordt voor sinter­
klaasverhaaltjes is een gemiste kans. 
8 Het beeindigen van a/le godsdienstoorlogen betekent dat de mens weer 
moet samenbrengen wat God gescheiden heeft: een onmoge/ijke opdracht 
a/s God werke/ijk bestaat. 
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l. General introduction 
l.l Adj11vants 
In 1796 Edward Jenner discovered a new type of medicine that proved extremely success· 
ful against the viral disease small pox. This new medicinal intervention, called vaccination, 
introduced a new and powerful tool against numerous infectious diseases, such as rabies, 
diphtheria, typhoid fever, plague, cholera, tuberculosis and measles. 
The principle of classical vaccination is based on inoculation of foreign biological material 
(=antigen) that induces immunity against infectious diseases without causing pathogenic 
symptoms. 
Vaccines may consist of live attenuated pathogens, which are still able to replicate. These 
replicating attenuated pathogens may cause clinical symptoms on a limited scale and 
trigger the immune system to build a protective immunological response. However, these 
attenuated micro organisms may also cause unwanted disease by reverting to a viru· 
lent phenotype. The risk of reversion to virulence limits the use of these live attenuated 
vaccines. 
As a result, there is a growing need for vaccines based on killed or inactivated antigens, 
so-called inactivated vaccines. Inactivated antigens are unable to replicate, unable to revert 
to virulence and therefore not pathogenic. Unfortunately, these antigens show little or no 
immunogenicity [2]. Therefore, most inactivated vaccines need repeated administrations 
or contain additional substances to help improve vaccine efficacy. These additional 
substances are called "adjuvants" (from the Latin, adjuvare = to help). 
Originally Ramon [1] described adjuvants as "substances used in combination with a 
specific antigen that produce more immunity than the antigen alone". This is a rather broad 
definition. Ramon demonstrated that addition of various types of substances, such as bread 
crumbs, agar, starch oil, lecithin or saponin were able to increase immunity compared to 
injection of antigen alone. Now, after more than 80 years the list of substances of possible 
adjuvants has grown enormously. However, due to considerations of safety, only very few 
types are generally accepted within human vaccination programs. Aluminium salts are 
(Aluminum salt is) still the gold standard for inactivated human vaccine formulations [2]. 
Remarkably, despite the broad range of identified adjuvant types the mechanisms of most 
vaccine adjuvants are poorly understood. A number of immunological theories may ex­
plain the critical mechanism underlying adjuvanticity, each with their own key concept. 
In general the concept is now accepted [3] that adjuvants can act predominantly as 
immunostimulatory agents stimulating the innate immune system or as vaccine delivery 
systems targeting antigen presenting cells (APC's). 
This concept is based on recent research emphasizing that a few immunological pathways 





Adj11vants initiate signals for imm11ne reactivity and amplify the response to an 
acceptable magnit11de: 
Vaccination aims to generate memory immune responses of adaptive B and/or T cells. 
Adaptive immune responses involve the activation of T helper cells which amplify and 
regulate antigen-specific immune reactions, such as those of B-cells and cytolytic 
T cells. T helper cells also amplify microbiocidal activity of innate immune effector 
cells such as macrophages. 
Hence, the production of antigen-specific T-helper cells is initially essential for adequate 
adaptive immunity. Activation and expansion of T helper cell clones are critically 
dependent of two signals: the delivery of antigen signals to T cell receptors ( = signal 1) 
and costimulatory signal induction ( = signal 2) in order to break tolerance. Adjuvants 
likely play an key role in the regulation of these two signals. 
• Signal 1: Reg11lation of imm11ne responses by antigen deliverance 
Since antigen-specific T cells only circulate between lymph nodes and spleen, antigen 
material inoculated by vaccination should reach peripheral lymphoid organs in order 
to be recognized by antigen specific T and B cells. Antigen in free form may drain 
directly to local lymph nodes through the afferent lymph vessels. It is also possible that 
peripheral antigen presenting cells (APCs), like local immature dendritic cells ( DCs), 
take up antigens and transport them to the lymph node. Upon arrival these dendritic 
cells have processed the antigen and become mature activated A PCs. They are able to 
prime naive antigen-specific T cells by processing the antigen in peptide fragments, 
which are then exposed in MHC molecules on the cell surface (o: Signal 1). 
According to the geographical concept and depot theories [4, S, 6] controlled release of 
antigen from the injection site or within the draining lymph node may facilitate signal 
1 expression in secondary lymph organs and is essential for durable immune response. 
However, absence of co-stimulatory signals (signal 2) such antigen presentation may 
lead to anergy, tolerance or deletion. 
• Signal 2: Co-stim11lation by tolerance-breaking molec11les 
Co-delivery of signal 2 molecules in the form of soluble cytokines or membrane-bound 
surface molecules prevents signal 1 from leading to T-cell tolerance or non- respon­
siveness. Innate immune cells and certain types of APCs or activated T cells are able to 
produce these types of molecules. Production of these signal 2 molecules is induced 
by a so-called "signal O". The origin of signal O is the evolutionary conserved non-self 
signal, based on signature molecules of groups of foreign micro-organisms, which are 
recognized by pathogen recognition receptors ( PRRs) present as circulating soluble 
immune molecules or expressed on the surface of innate immune cells [7]. Toll-like 
receptors (TLR's) are typical examples of PRRs. TLRs have evolved to recognize specific 
sets of molecules, including components of the bacterial cell wall and endocytosed 
nucleic acids (such as DNA, RNA, CpG motifs). 
Signal 2 may also be induced by so-called "danger signals" [8, 9]. Danger signals can 
be released from organelles of cells undergoing necrotic death within stressed, or 
damaged tissue. Although such organelles or molecules from dead cells are not well 
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defined at the molecular level, likely candidates responsible for immune activation 
include mitochondrial and nuclear fractions of necrotic cells as well as heat shock 
proteins, cellular DNA or uric acid [IO). 
Adj11vants evoke signals directing immune response polarization 
• Signal 3 
The two-signal theory is well accepted and sustained by numerous publications. 
Apart from signals 0, I and 2 a third signal has been defined to indicate the quality of 
immunological reactions. Especially T helper cells play a key role in regulating the 
quality of immunity. They can polarize the immune responses into either cell-mediated 
or humoral type responses, roughly reflected by a Thi- or Th2-type of response, 
respectively. The origin of the instructive signals for Thl/Th2 polarization may be 
found in the upper part of the cascades leading to APC activation, although the mode 
of delivery of antigen in secondary lymphoid tissues may also regulate the extent 
of this immune polarization. Also antigens or their structure may inherently affect 
the quality of the immune response. Besides the route of administration, the type of 
adjuvant may strongly influence the quality of the immune response [ 11). 
The importance of antigen delivery 
As described above, according to the geographical concept [4, 5, 6) an immune response 
to a given antigen critically depends on the initial delivery of the antigen within 
secondary lymph tissues by either resident or immigrating antigen presenting cells or 
in free form(= signal 1 ), which is a central theme in this thesis. Duration of protective 
immunity is often based on the presence of circulating neutralizing antibodies which 
prevent microbial infection of host target cells [I 2). The maintenance of antigen-specific 
antibodies in the circulation for a prolonged period of time requires persistent or 
repeated exposure of B-cells to antigen or the persistence of long-lived plasma cells. 
Antigen-persistence can be achieved by the sustained or pulsed release of antigen from 
(encapsulated) depots. Such a persistent release of antigen is expected to maintain a 
high level of antibody production without the need for frequent, unpractical booster 
immunizations. In addition, encapsulation of antigen may overcome its immediate 
neutralization by maternal antibodies, which are known to prevent active parenteral 
immunization [ 1 3). 
Various pharmaceutical formulations have been developed as vaccine antigen 
delivery systems. Several formulations, like antigen-entrapping liposomes or microcap­
sules based on the biodegradable Poly Lactic Acid - Poly Glycolic Acid Copolymer can 
provide a depot effect [14, 15). Unfortunately, the large-scale manufacturing procedures 
of these particulate delivery devices may be complex. Alginate microspheres seem to be 
very attractive. The alginate matrix can protect the antigen from hostile environments 
and also possesses mucoadhesive properties, which could increase the contact time 
between alginate microspheres and the absorptive epithelium or the M-cells within 
mucosa associated lymphoid tissue (MALT) [40, 4 1, 42). Fundueanu et al. [43) described 
the preparation and characterization of Ca-alginate microspheres using an emulsion 
technique. This technique allows to obtain microparticles (average diameter of 350 




particles with a suitable morphology (spherical shape) were only effectively produced 
at a temperature of 60 "C, a temperature which may damage the antigen integrity. 
When aiming at induction of durable high-titered antibody formation following a 
single immunization, water-in-oil (W/O) emulsions represent a very attractive delivery 
system for vaccine antigens, which is also suitable for large-scale production. The need 
for cost-effective, one-shot immunizations in certain veterinary species explains the 
extensive use of such emulsions in veterinary vaccines. The present thesis is focused 
on the pharmaceutical features of oil emulsions and their structure-adjuvant activity 
relationship in vivo. 
l.Z Oil-based emulsions as vaccine adjr,vants 
1.2.1 Water-in-oil emulsions 
Emulsions are colloidal systems based on a mixture of (at least) two fluids that form a 
multi-phase complex. Water-in-oil (W/O) emulsions are two phase systems consisting of an 
aqueous, discontinuous phase dispersed as small droplets within a continuous oil phase 
Figure 1). To stabilize this dispersion one or more emulsifiers are added. An emulsifier 
localizes at the interface between the water and oil phase, since it contains a hydrophilic 
and a hydrophobic group, the latter often composed of a fatty acid chain. W/O emulsions 
are produced by mixing the water phase into the oil phase under high shear stress. Usually 
a colloid mill based on a rotor/stator principle is used (Figure 2). Emulsifiers may be located 
initially within the water phase or oil phase, depending on their hydrophilic/ lipophilic 
character. 
Figure 1. 
Microscopic view of water-in-oil emulsion 
(1 000x magnification). 
The efficacy of W/O emulsions as vaccine formulations is likely based on the capacity to 
stimulate an immune process as a result of controlled {prolonged, pulsed) release of anti­






1.2.1 a. Immune stimulation 
oil phase: 
oil + emulsifiers 
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Figure 2. 
Production of vaccine based on 
water-in-oil emulsion. 
W/0 emulsions are known to trigger an inflammatory response at the injection site. 
Possibly, this leads to critical recruitment and activation of APCs before they migrate towards 
local draining lymph nodes to present antigen to cognate T and B lymphocytes (16). Besides 
paraffin oil, a wide range of lipoid substances including hexadecane, squalene, pristine, etc., 
possesses adjuvant activity for a variety of antigens [17). Increasing the length of the fatty 
acid carbon chain favors adjuvant activity (18), although this may depend on the type of 
immune response. However, systematic substitution of chemically defined straight- chain 
saturated hydrocarbons (alkanes or paraffins) of varying length for the standard mineral 
oils revealed that intermediate hydrocarbon chain lengths of 15 to 20 carbons possessed 
superior adjuvant activity for induction of experimental allergic encephalomyelitis ( 1 9]. 
In general, saturation of the fatty acid carbon chain favors adjuvant activity (18]. Unsaturated 
or oxygenated lipids are weaker adjuvants than their saturated/desoxy analogues (17], 
possibly due to their susceptibility to degradation. High reactivity of these unsaturated 
molecules may affect stability of antigen material. Several highly reactive molecules, 
including malonyl dialdehyde, generated as a result of oxidation of unsaturated squalene, 
are capable of cross-linking proteins [20). Miles et al., (21] described loss of vaccine 
immunogenicity due to development of cross-linked proteins when emulsified with squalene 
based adjuvant. 
Therefore, nonreactive oils, like mineral oil, may guarantee better stability of antigens in the 
emulsion for extended periods of time at body temperature, which is likely necessary for 
the superior adjuvant effect of W/0 emulsions, thereby allowing the slow release of small 
amounts of antigen over time, as suggested by Herbert (22). 
1.2.1 b. Controlled release of antigen 
In most cases, vaccine antigens are harvested as suspended or dissolved material in aqueous 
media and therefore (almost) always located in the water phase. Since this water phase is 
dispersed in the oil phase, antigen material is trapped and not immediately available after 
inoculation. Accordingly, W/0 emulsions typically retain the antigen at the site of injection, 







Especially this rate of antigen release from the injection sites is assumed to be a crucial 
factor in maintaining antigen-specific immune responses [23], as elegantly elucidated by 
the work of Herbert [22]. He compared the effects of one immunization with a single dose 
of a vaccine given in a W/O emulsion with the effects of multiple immunizations of minute 
amounts of antigen dissolved in saline in parallel groups. Both, the multiple immunization 
regimen, injected daily over a period of 50 days, and the single high dose immunization 
evoked antibody titers with almost identical kinetics. However, antibody titers gradually 
declined following arrest of the daily injections, while in animals injected once with the 
depot the serum titers showed a durable response. Hence, a slow release mechanism 
of minute amounts of antigen could very well explain the efficacy of depot-forming oil 
emulsions. 
Two major mechanisms of antigen release can be distinguished for W/O emulsions: 
i) diffusion and ii) emulsion rupture {24, 25]. Rupture can be avoided by improving stability 
of the emulsion. The composition of the emulsion, like water/ oil ratio or amount and type 
of emulsifiers as well as the manufacturing process, are essential parameters that strongly 
influence the stability of the emulsion. 
A diffusion-mediated release implies migration of antigen from the internal water phase, 
where the antigens are originally located, through the interfacial barrier of surfactants into 
the oil phase of the emulsion [251. Ultimate release of the antigen from the emulsion is 
realized by diffusion from the oil phase into the extra cellular space at the injection site 
or within the draining lymph node. Alternatively, liberation of antigen or its fragments 
may occur from endocytic compartments after endocytosis of W/O fragments by recruited 
APCs. We and others have demonstrated that depot-forming emulsions release probably 
only minute amounts of antigen in in-vitro systems [26, 27]. It is of interest to note, that 
under in-vitro conditions antigen included in a W/O emulsion is not released for a period 
of more than 3 weeks, while given in-vivo such a formulation evokes significant antibody 
responses within 3 weeks after inoculation [27]. By contrast, antigen dissolved in saline 
or antigen formulated with an oil-in-water adjuvant emulsion is released quickly in vitro, 
but evokes less antibody responses despite immediate availability of antigen [27]. Hence, 
variations in emulsion structure can profoundly influence antigen release rates and ensuing 
immune responses [ 28]. 
Apart from the chemical composition, viscosity and droplet size form major parameters 
influencing antigen release characteristics of emulsions. 
Viscosity 
Most W/O emulsions for parenteral injection contain a 60 - 70 % of oil phase. This 
amount of oil is necessary to create a stable emulsion with an acceptable viscosity, i.e. 
the emulsion is easily injectable. A W /0 emulsion containing only 50 % of oil phase is 
difficult to inject because of its high viscosity; Freund's complete and incomplete 
emulsion, for example, are both based on a water/oil ratio of 50/50. Moreover, high 
viscosity may negatively affect the antigen release rate and vaccine safety. 
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Droplet size 
The water droplet size can be controlled by variations in the method of preparation. Low 
shear mixing generally results in emulsions with a droplet size of up to 50 µm, while 
emulsions formulated under high shear forces contain approximately 1 µm size droplets. 
The droplet size may affect the antigen release rate. Smaller droplets create a larger 
surface area and therefore an increased release can be expected. In addition, within 
a small droplet formulation the amount of droplets increases, thereby increasing the 
viscosity of the emulsion. 
1.2.1 c. Safety 
Local reactions and residues represent major safety concerns for vaccine formulations 
based on W/O emulsions. The prolonged presence of oil may induce necro-ulcerative lesions 
at the injection site [29). Especially the type of oil (metabolizable or non-metabolizable), 
the type of emulsifier and their purity are expected to determine the extent of adverse 
reactions. Also the percentage of oil in the emulsion is likely related to its residues and 
hence its safety, besides its influence on efficacy (22, 30). 
In view of the local reactions at the injection site, the replacement of mineral oils by 
non-mineral, metabolisable oils would be desirable. Metabolisable oils, such as vegetal 
oils or (semi-)synthetic oils like medium chain triglycerides or oleyl oleates are more likely 
to be removed eventually from the injection site by macrophages or enzymatic activity. 
Higher susceptibility to degradation may explain why unsaturated or oxygenated lipids 
are weaker inducers of late residues and associated local reactions. By contrast, mineral 
oil injected in the form of a W /0 emulsion does not disperse and is not easily degraded. 
Mineral oil, intended for general pharmaceutical use is a so-called "white mineral oil", 
which is obtained by refining crude paraffin oils, removing aromatic, unsaturated and other 
reactive hydrocarbons as well as sulfur and nitrogen derivates and volatiles. Hence, mineral 
oil of pharmaceutical quality is a mixture of hydrocarbons with different carbon chains. 
Especially the length of these carbon chains is crucial for the safety of the vaccine. Small 
chains (< C 1 4) have been shown to induce more local reactions (3 1 ). Residues of mineral 
oil based emulsions at the injection site can be minimized by increasing the dispersibility 
of the emulsion. This can be achieved by decreasing the viscosity of the emulsion or by 
addition of a hydrophilic emulsifier. Unfortunately, these adaptations may negatively affect 
the depot properties of the emulsion. 
1.2.2 Oil-in-water emulsions 
In contrast to W /0 emulsions, oil-in-water (O/W) emulsions are rather well-tolerated. These 
emulsions consist of an aqueous continuous phase that contains dispersed oil droplets as 
discontinuous phase; the opposite structure of W/O emulsions (Figure 3). O/W emulsions 
are hydrophilic and show relatively low viscosity (usually < 30 cP). Since the oil phase is 
the discontinuous phase, i.e., O/W emulsions contain low amounts of oil, between 5 - 30 %. 
These facts explain their safety. Antigen material located in the continuous water phase is 
not trapped, but rather, becomes immediately available after inoculation. Therefore, O/W 
emulsions characteristically show an early onset of immunity by rapid release of antigen. 
In case of bacterial antigens containing LPS or other inflammatory fragments, this rapid 
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Figure 3 . 
Microscopic view of oil- in-water emulsion 
(1 000x magnification). 
Since O/W emulsions do not exhibit controlled release features, which may theoretically 
facilitate signal 1, one might expect that oil droplets in O/W adjuvant contain immunos­
timulatory molecules that lead to co-stimulation (signal 2), although a direct immune 
activating receptor has not been de monstrated. M F 5 9  is a well-known example of a 
commercial adjuvant based on 0/W emulsion. It is a critical component in FLUAD� the 
MF59-adjuvanted human influenza vaccine of Novartis. MF59 contains squalene, which 
is the primary component of shark liver oil and the emulsifiers Polysorbate 80 and 
Sorbitantrioleate (321. None of these components are known as direct immunostimulatory 
molecules. Investigations of Depuis et al. [ l  6) suggest that the oil droplets of MF59 
adjuvant interact with APCs at the injection site and move to the draining lymph nodes, 
where the interaction of APCs with T cells is facilitated. Hence, similar to W/O emulsions, O/W 
emulsion may induce and affect signal 1, but apparently with less efficient duration, 
possibly due to lack of depot properties. 
1.2.3 Double emulsions 
Water-in-oil-in-water (W/O/W) emulsions, referred to as double-oil emulsions, contain depot 
properties and display acceptable safety features as a result of their favorable dispersion 
properties.W/O/W emulsions are formulated in two steps: first a primary W/O emulsion is 
prepared and subsequently this W/O emulsion is mixed into a secondary aqueous phase, 
containing a hydrophilic emulsifier (Figure 4). W/O/W emulsions are usually more safe than 
W/O emulsions, because W/O/W emulsions are more easily dispersed and diffuse more 
readily from the injection site. The depot properties of a double-oil emulsion are ensured as 
long as the antigen is localized in the primary water phase of the W/O/W emulsion. Double 
emulsions may show adjuvant activity and duration with limited local reactions or residues. 
However, the major disadvantage of double emulsions is their inherent lack of stability (33]. 
Therefore they are not widely used in vaccine products. 
1.3 Freunds adjuvants 
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Figure 4. 
Microscopic view of water-in-oil-in-water 
emulsion (1 000x magnification). 
W/0 emulsions represent one of the best ever-devised controlled delivery system for 
vaccine antigens and are therefore extensively used in veterinary vaccines and experimental 
vaccination studies. The first description of the use of oil emulsions in vaccine 
formulations dates back to 19 1 6, when Le Moignic and Pinoy vaccinated mice with 
inactivated Salmonella typhimurium in an emulsion of water and Vaseline oil [34]. Decades 
later Jules Freund developed the famous Freund's incomplete (FIA) and complete adjuvant 
(FCA), both well-known prototypes of W/0 emulsions based on paraffin oil, in the absence 
or presence of heat-killed Mycobacteria, respectively [4]. 
The classical F IA consists of a mixture of mineral oil and mannid monooleate as emulsifier. 
The ratio mineral oil / Mannidmonooleate is 85/ 1 5  % v/v, but ratios of 90 % oil and l 0 % 
emulsifier have also been described. FCA is similar to FIA, except for the addition of heat­
killed Mycobacterium tuberculosis or butyricum, suspended in the oil mixture. FCA is often 
applied as a single intramuscular injection or multiple subcutaneous injections. Booster 
injections can be given in FIA. 
Although Freund's adjuvants are efficacious, problems may occur due to formulation dif­
ficulties. Since the water/oil ratio of this adjuvant is 50/ 50, the final emulsion is rather 
viscous and not easy to administer. Moreover, neither stability of the emulsion nor the re­
producibility can be guaranteed. Due to its high viscosity no standard equipment is used to 
produce the emulsion, but it can be prepared by repeated passage of the mixture of oil and 
water (containing antigen) through a transfer needle inserted between two syringes, pro­
voking a shear force. As a result of the repeated passages the emulsion becomes gradually 
thicker. This production technique is therefore rather difficult to reproduce. The quality of 
the final emulsion strongly depends on the shear rate and the pressure applied to the piston 
of the syringes. FCA/ FIA has been used extensively in laboratory animals since the 1 950s, 





FCA was one of the first types of adjuvant that proved to stimulate cell-mediated immunity 
(Th i) in addition to its ability to augment the humoral response (Th2). A study of Yip et 
al. (35) clearly showed that W/O emulsions like IFA induce a Th2 type response. Addition 
of Mycobacterium Tuberculosis may exceed a threshold of magnitude of stimulation that 
results in a switch towards Th i type immunity. Shibaki et al (36) discovered the same 
effect when mice were immunized with chicken ovalbumin emulsified with either IFA or 
CFA. When assessing lymph node cells on day 7, no difference in antigen specific 
proliferation was observed in mice treated with either IFA or CFA. However, on day 28 ELISA 
analysis revealed that T cells from mice primed with CFA produced Th i cytokines more 
dominant when compared to IFA. 
Switching the balance of an antigen-specific i mmune response from a type-2 towards 
a type- I mode by addition of inactivated Mycobacteria in FCA, may be explained by either 
recruitment of distinct types of Th i instructing antigen presenting cells (APCs) or 
instructive Th-I -polarizing effects of the microbial emulsion components on the recruited 
APCs. Such a polarizing activity has been attributed to recognition of agonistic 
mycobacterial structures by PRRs. (37). 
Thus far, a clear role for the emulsion to act as a vehicle has net been revealed Freunds W/O 
based adjuvants, despite thorough investigations. Co-stimulating signal 2-inducing ligands 
or their receptors have not been defined for the rather inert IFA-type W/O emulsions, 
lacking microbial components. Therefore, besides the above-mentioned immunostimu­
latory activity, the antigen maintenance at the injection site may be important for a 
W/O-induced co-stimulation-independent immune response and its duration (38). 
The emulsion vehicle of the Freunds W/O based adjuvants is thought to act as an inert 
depot from which the emulsified antigen is slowly released for a prolonged period of time 
to supply the site of antibody production, a process that has been considered crucial in 
maintaining immune responses (23). Indeed, W/O emulsions show depot characteristics for 
incorporated antigens, because in this two-phase emulsion system the antigen-containing 
aqueous phase is dispersed as small droplets in the continuous oil phase. Herbert (6) 
attempted to mimic a slow release mechanism by daily injections of tiny doses of 
ovalbumin alone in mice, and noted an antibody production profile similar to a single 
full-dose ovalbumin formulated in a W/O emulsion. Interestingly, the antibody level in the 
circulation dropped soon after the daily injections were stopped. 
Freund studied the role of the depot function in rabbits by measuring antibody 
formation after surgical removal of the vaccine from the site of injection. Excisions 
performed between 30 minutes and four hours after injection resulted in a decrease of the 
immune response when compared to the response in animals in which the injected areas 
were not removed. Remarkably, excisions performed after one or more days did not seem 
to affect the antibody response (39). Therefore, there is still no conclusive insight as to the 
essence of slow release, explaining immune stimulating features of Freund's adjuvants, or 
W/O emulsions in general. 
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1.4 Outline of this thesis 
W/0 emulsions are routinely used in many poultry vaccines. Despite numerous 
investigations, little is known about the mechanisms responsible for adjuvant activity 
of the W/0 emulsion as a vaccine adjuvant. The structural requirement as well as the 
cellular and molecular immunological mechanisms within the host remain poorly 
understood. Indeed, this powerful immune modulatory formulation has been shrouded in 
obscurity and is often referred as an example of "the immunologist's dirty little secret". 
As local reactions and residues represent major safety concerns for vaccines based on 
W/0 emulsions, there is a demand for an alternative adjuvant, preferably with a high 
efficacy similar to W /0 emulsions. Understanding the mechanism underlying W /0 
emulsion activity may help to further improve their formulation, thereby diminishing 
or eliminating potential hazards. Alternatively, such insight will be highly useful in 
developing novel vehicles. 
The aim of this thesis is to investigate potential mechanisms responsible for the high 
efficacy of W/0 emulsions as a vehicle for inactivated vaccines. Pharmaceutical 
characteristics of the emulsion and immunological parameters associated with emulsion 
variants were addressed, together with in-vitro antigen release studies. Unless indicated 
otherwise, all in vivo studies were performed in three-weeks old Specific Pathogenic 
Free (SPF) chickens. Vaccines were inoculated by intramuscular injection. Most vaccines 
contained at least one of three types of inactivated viral avian antigens: Newcastle 
disease virus (NDV) strain Clone 30, infectious bronchitis (IBV) strain Massachusetts 4 1  
and inactivated infectious bursa) disease virus (IBDV) strain D78. Local reaction scores 
and and antigen-specific serum responses were determined using standardized methods 
established at lntervet, Boxmeer, The Netherlands. 
In order to unravel the mechanism of W/0 emulsions, first the relationship between 
certain parameters within variants of Freund's incomplete adjuvant-type W/0 emulsions 
and associated levels of vaccine efficacy and safety were investigated. 
Chapter 2 describes the study of pharmaceutical determinants of this antigen-carrier 
system, including the W/0 ratio and the droplet size of the emulsion in relation to 
levels of vaccine efficacy and safety (Figure 5). Especially the comparison of type of 
oil, -metabolizable versus non-metabolizable-, might reveal the importance of the type of 
oil and contribute to the rational design of future vaccine formulations that contain no 
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Study of pharmaceutical determinants of W/O emulsions as antigen-carrier system, described in chapter 2. 
However, the study described in chapter 2 does not reveal whether the immune response 
was caused by antigen-depot properties of the W/0 formulations, or by the immune 
stimulating properties of the components of the emulsions, or a combination of both. 
Therefore, a study was designed in which the influence of slow release capacities of antigen 
on the immune response could be determined independently of the immune stimulating 
properties of the components of the vaccine formulation. In this study a composition of 
exactly identical components, in identical amounts, was processed to generate structurally 
different W /0, 0/W or W /0/W emulsions (Figure 6). Based on differences in antigen-release 
properties between W/0, OW and W/0/W emulsions, anticipated differences in immune 
response could be related to these specific release characteristics. Results of this study are 
described in chapter 3.  
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antigens 
Study of antigen-release and immunostimulating properties of W/0, 0/W or W/0/W emulsions as 
antigen-carrier system, described in chapter 3. 
If W/0 emulsions exhibit special antigen release characteristics that play an important role 
in immune stimulation, what are they? ls it possible to mimic this release mechanism by 
daily injections of minute doses of antigen, like Herbert's study of 1 966 in mice? Chapter 4 
describes a study that revisited the dose and regimen for viral antigens in chickens (Figure 
7). Our aim was to compare antibody responses in repeatedly injected poultry, -receiving 
fractionated doses of antigen-, with responses after only one injection of the full antigen 
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Comparison of antibody responses In repeatedly injected fractionated doses of antigen-, with responses 
after only one injection of the full antigen dose formulated in either a W/O emulsion or in saline, described 
in chapter 4. 
In-vitro release characteristics of W/O emulsions showed no detectable antigen release dur­
ing the firs t three weeks. The lack of detection of antigen release might be result of a low 
antigen concentration in the W/O emulsion vehicle. Using a low antigen concentration, the 
majority of the microspheral water droplets dispersed in the oil would contain no antigen 
material. These empty droplets might block antigen release. If this is the case, an increase of 
the concentration of antigen might be possible without affecting the release characteris tics, 
which may be characteris tic for the efficacy of these vehicles. 
Increase of the concentration of antigen corresponds to decrease of dosage volume. Espe­
cially for vaccines based on W/O emulsions, minimizing dosage volume corresponds to 
minimizing local reactions at  the injection site. Chapter 5 describes the efficacy and safety 
as a resul t of variations in the dosage volume of W/O based vaccines (Figure 8). 
Figure 8. 
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Study of efficacy and safety as a result of variations in the dosage volume of W/O based vaccines, described 
in chapter S. 
Finally, in chapter 6 the most important observations reported in this thesis are 
summarized and perspectives for future studies are discussed. 
2 2  
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Water-in-oil (W/0) emulsions are known as most effective adjuvants to generate high and 
durable antibody responses to vaccine antigens following a single immunization. However, 
their structural requirements remain poorly understood. Here we addressed the significance 
of certain pharmaceutical characteristics including water/oil ratios, - ranging from 60/40 
to 30/70 (% w/w) -, droplet size and type of oil, i.e. non-metabolizable (Mineral Oil) versus 
metabolizable (Miglyol 840). Stability of emulsions was accomplished by the use of a 
polymeric emulsifier. Distinct W/0 emulsions were formulated with inactivated (i) 
Infectious Bronchitis virus (ilBV) and Newcastle Disease virus (iNDV), and evaluated in 
immunized chickens for magnitude and duration of in vivo antiviral antibody formation 
and local reactions. A high Mineral oil content proved most effective for antibody response 
formation. In general, a larger droplet size evoked higher antibody responses for both oil 
types. lnoculum residues proved lower using biodegradable Miglyol, when compared to 
Mineral Oil, for all emulsion variants. Especially water-to-oil ratio and droplet size may 
provide useful parameters for improving (antiviral) antibody production by W/0 
emulsions. 
Keywords: oil emulsions, vaccine, antibody responses, adjuvant, release. 
Introduction 
When aiming at induction of durable high-titered antibody formation, water-in-oil (W/0) 
emulsions represent one of the best ever-devised "one-shot" delivery system for vaccine 
antigens. However, W/0 emulsions are predominantly used in veterinary vaccines and 
experimental studies. The first evidence of the use of oil emulsions in vaccine formulations 
dates back to 1 9 1 6, when Le Moignic and Pinoy vaccinated mice with inactivated Salmonella 
typhimurium in an emulsion of water and Vaseline oil ( 1 ). Decades later Jules Freund 
developed Freund's incomplete and complete adjuvant, both well-known prototypes of W/0 
emulsions based on paraffin oil, in the absence or presence of heat-killed Mycobacteria, 
respectively (2). W/0 emulsions have been widely used as immunopotentiating delivery 
systems for veterinary vaccine antigens, notwithstanding their risk for the occurrence of 
adverse effects at the site of injection (3). However, these severe side effects prevented use 
in human vaccines. Still, certain W/0 emulsions are currently tested in clinical trials as 
potentiators of therapeutic cancer vaccines (4). In spite of their long history and frequent 
use in veterinary medicine and laboratory animals, knowledge about the immunological 
events underlying its adjuvanticity remains scanty. In addition, little is known about the 
structural and physico-chemical characteristics of W/0 emulsions that are critical for their 
enhancing effect on antibody-formation. 
Antigen maintenance at the injection site may be important for a costimulation-independent 
immune response and its duration (5). W/0 emulsions typically retain the antigen at the 
site of injection, thereby performing a depot function by preventing the antigen from rapid 
release [6). Especially this rate of antigen release from the injection site is assumed to be a 
crucial factor in maintaining antigen-specific immune responses [7) as elegantly elucidated 






of a vaccine given in a W/0 emulsion we re compared with the effects of multiple 
immunizations of minute amounts of antigen dissolved in saline. Both, the multiple 
immunization regimen, injected daily over a period of 50 days, and the single administration 
in adjuvant evoked antibody ti ters with a lmost identical kinetics. However, antibody ti ters 
rapidly declined following arrest of the daily injections, while in animals injected once with 
the depot the serum responses showed durable levels. Especially, physico-chemical 
p roperties of the emulsion, such as the viscosity, the droplet size and hydrophobicity are 
likely to influence the kinetics of antigen release. 
Apart from these depot-dosing effec ts, W /0 emulsions a re known to trigger an inflammatory 
response at the injection site , possibly leading to recruitment and activation of antigen 
presenting cells before they migrate towards local draining lymph nodes to p resent antigen 
to cognate T and B lymphocytes [9]. The addition of specified microbacte rial products to 
W/0 emulsions, such as inactivated Mycobacteria in Freund's Complete Adjuvant, switches 
the balance of an antigen-specific immune response from a type-2 towards a type- I mode 
[ 10]. This swi tching effec t may be explained by, ei ther recrui tment of different  types of 
antigen presenting cells (APCs), or instructive polarizing effects of the emulsion components 
on the recrui ted APCs. 
Local reactions and residues a re major safety concerns for vaccine formulations based on 
W/0 emulsions. The presence of oil may induce necro-ulcerative lesions at the injection si te 
[ 1  I ]. Especially the type of oil (metabolizable o r  non-metabolizable), the type of emulsifier 
and their pu rity likely codetermine these adverse reactions. Also the amount of oil present 
in the emulsion may be rela ted to i ts residues and hence i ts safety, besides i ts influence on 
efficacy [6, 1 2]. 
In the present s tudy pharmaceutical determinants of the antigen-carrier system, 
Including the type of oil, the water- to-oil ratio and the d rople t size of the emulsion - have 
been investigated in relation to their biological effects, i.e. e fficacy in antiviral antibody 
formation and safety. The formulations, administered in tramuscularly to 3 - 4 week-old 
chickens, contained the inac tivated antigens of Infectious Bronchi tis virus ( IBV), and New 
Castle virus (NOV). These viral antigens a re both routinely administe red in Mineral 
Oil-based emulsions to layer chickens requiring durable antibody tite rs under acceptable 
local reactions. 
Our da ta demonstrate the rela tionship between certain pharmaceutical parameters within 
variants of Freund's incomplete adjuvant-type W/0 emulsions and levels of vaccine safety 
and efficacy. Information on the essential features of emulsion composition may contribute 
to the rational design of future vaccine formulations that contain no mineral oil, but are 
s til l efficacious and safe. 
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Materials and methods 
Materials 
Mineral oil (Marco! 52 from Exxon, USA) and Miglyol 840 (Medium Chained Triglyceride from 
Huls, Germany) are the type of oils tested. A polymeric emulsifier, Arlacel (Uniqema, UK), in 
a concentration of 3 % w/w was used as surfactant in all the vaccines. The Arlacel was mixed 
into the oil phase at 60 'C. 
Two types of formalin-inactivated viral avian antigens were examined: Newcastle Disease 
Virus (NOV), strain Clone 30 and Infectious Bronchitis (IBV), strain Massachusetts 4 1 ,  
produced i n  eggs. The total concentration o f  virus suspension used was 18 % w/v o f  the 
final vaccine. The aqueous phase, containing the virus suspension was diluted with 0.0 1 
M Phosphate buffer, pH 7.2 
Preparation of the emulsions 
Emulsions (100 ml for each batch) were prepared according to standard procedures ( 1 3, 14]. 
Two types of emulsions with distinct droplet size were prepared. For high shear emulsions, 
mixing was performed with high shear forces at 20.000 r.p.m. using the Ultra Turrax Type 
T25 (!KA, Germany), resulting in water droplets of approximately 1 µm. During the 
emulsification process the temperature of the emulsion was monitored. The process 
continued for 4 - 5 minutes, until a temperature of 3 7  ·c was reached. For low shear 
emulsions, mixing of the aqueous phase into the oil phase was performed at 1000 r.p.m., 
for 5 minutes, using the Eurostar mixer (!KA, Germany) provided with a propeller blade, 
resulting in water droplets of approximately 1 - 40 µm. Variations of the water-to-oil 
ratios tested included 60:40 (except for Miglyol formulations), 50:50, 40:60 and 30:70 (all 
in % w/w). The droplet size of the emulsion was determined by interference microscopy 
at l000x magnification (Olympus, model BX50, Japan). The viscosity of the emulsions was 
measured at 25 ·c using a synchro viscometer (Brookfield, type LVT, Middleboro, MA, USA). 
Accelerated physical stability tests were performed by determining the appearance and 
microscopic view after storing the emulsions at 37 ·c during three weeks. 
Immunization of animals 
Groups of three-to-four week-old specific pathogen free (SPF) female White Leghorn 
chickens (n = 8 -10) were vaccinated intramuscularly with 0.5 ml of the vaccines, in the 
breast muscle. Blood samples for serological tests were taken at weeks 3, 6, 9 and 1 2  after 
vaccination. Virus haemagglutination inhibition (HI) tests for NOV and IBV were performed 
to determine the levels of antiviral serum antibody titers. 
During the course of the experiment all animals immunized with the various emulsion 
vaccines were monitored for notable clinical symptoms. Local reactions at the injection site 
were monitored at 12 weeks after vaccination. The influence of the various emulsions on 
putative early inflammatory reactions at the injected muscle was examined by microscopy 
at 48 hours after inoculation. Histological evaluation of injection-induced responses was 
performed on haematoxylin-eosin (HE) -stained 5 µm paraffin sections of formalin-fixed 
muscle fragments dissected from injection sites. 
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Assays for serum antibodies 
Serum levels of NOV- and IBV- spec ific ant ibod ies were determined by haemagglut ination 
inhibition (H I) assay. Serial two-fold serum dilut ions were prepared in microtiter plates 
and mixed w ith an equal volume containing 8 haemagglutinating units / 50 µI NOV or IBV 
antigen. T iters were expressed as the reciprocal of the highest dilution that g ives complete 
inhibition of haemagglut inat ion of red blood cel ls ( 1  % (v/v) in buffered saline. Samples 
were regarded to be posit ive for inhibit ion of haemagglut ination at dilution � l: 2 (NOV) 
and � l : 16 ( IBV), respect ively. 
Kinetics of antigen release 
Inherent antigen·re lease characteristics of the various formulat ions were determined in 
release kinet ics studies, performed in vitro. The different vacc ine-formulations contained 
inact ivated Infectious Bursa( D isease Virus ( IBDV), strain D78, at a concentration of 1000 
ELISA-units/ml. IBDV belongs to the B irna v ir idae family and was chosen because of its high 
stabil ity. IBDV strain D78 was produced on Vero - cells . 
To simulate in vivo condit ions , 5 ml of these IBDV-vaccines were mixed in 15 ml isotonic 
0.01 M Phosphate buffer, p H =  7.2 and stored at 3 7 ·c while st irring. Over a period of 1 2  weeks 
samples were taken at different t ime points from the buffer·medium. A filter was used to 
exclude emuls ion-droplets in the sample. 
Determination of the antigenic mass of IBDV in the samples was performed by R-63-ELISA. 
Wells of polystyrene microtiter plates, coated w ith neutraliz ing monoclonal ant ibody R-63 
were filled w ith sample and reference ant igen in serial d ilut ions. Biotin-labeled antibody 
(R-63-biot in) was used to detect IBDV antigen captured by the coated ant ibodies. 
Statistical analysis 
Comparison of means of serum titers was performed using analysis of variance (ANOVA) 
with least significant difference ( LSD) as multiple comparisons test. A ll results were 
generated us ing SAS (version 8.2) software. D ifferences were cons idered s ignificant if P was 
less that 0.0 5. 
Results 
In order to s tudy the relat ionsh ip between dist inct formula tion structures and immunizat ion 
effic ienc ies we generated emulsions with two different droplet s izes, formulated w ith two 
oil-types and various water-to-oil rat ios (see table l and Figure l A and B). Accelerated 
phys ical stabil ity test showed that none of the samples tested showed emulsion breakdown 
after test ing. These stable emulsions allowed us to address structure related immunization 
efficac ies and their local reactions. 





Table 1 :  
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W/0 ratio ('J6 w/w) mixing shear (rpm) Viscosity (cP) Droplet size 
50/50 1 000 84 l - 1 5 µm 
40/60 1 000 45 l - 20 µm 
30/70 1 000 30 1 - 20 µm 
50/50 20000 1 1 5  ± 1 µm 
40/60 20000 5 3  ± 1 µm 
30/70 20000 30 ± l µm 
60/40 1 000 1 37 1 - 40 µm 
50/50 1 000 68 1 - 40 µm 
40/60 1 000 42 1 - 40 µm 
30/70 1 000 28 1 - 40 µm 
60/40 20000 243 ± 1 µm 
50/50 20000 94 ± 1 µm 
40/60 20000 50 ± 1 µm 
30/70 20000 30 ± 1 µm 
Viscosity and droplet size of various emulsions based on Miglyol 840 or Mineral Oil . 
Figure l A: 
W/0 emulsion prepared under high 
shear conditions (1 000x magnification), 
representing a high shear emulsion 
appearance independent of oi l type 
or W/0 ratio. The size of the droplets 







Figure l B: 
W/O emulslon prepared under 
low shear conditions 
(l 000x magnification), 
representing a low shear emulsion 
appearance independent of oil type 
or W/O ratio. The size of the droplets 
varies between l and 40 µm. 
Effects of various emulsions on local reactions 
During the course of the experiment all animals immunized with the various emulsion 
vaccines appeared healthy without notable clinical symptoms. Histopathological investigation 
at 48 hours after i noculation showed that the Miglyol-based emulsions caused a considerable 
local influx of  predominantly macrophage-type cells (Figure 2A), which appeared to be more 
severe at higher amounts of Miglyol (not shown). In  contrast, M ineral Oil, visible as relatively 
large oil droplets, had caused only a modest influx of macrophage-type cells after 48 hours 
(Figure 2B). Interestingly, at 1 2  weeks after inoculation M ineral Oil emulsions still showed 
more local reactions and residues in the form of small droplets, when compared to M iglyot 
840 emulsions (data not shown). For both types of emulsion neither the W/O ratio nor the 
viscosity seemed to influence the i ntensity of the local reaction. When compared to tow 
shear preparations, Mineral Oil emulsions prepared under high shear conditions showed 
an augmented local reaction, whereas Miglyol 840 emulsions prepared under high shear 
conditions gave rise to a decrease in  local reactions, relative to low shear M iglyol 
preparations. Residues of the inoculum containing Mineral Oil were still visible after 
1 2  weeks, in contrast to Miglyol emulsions, which showed no residues at this time point 
(not shown). 
These data illustrate that a rapid and prominent early influx of inflammatory cells, as evoked 
by Miglyol within 48 hours after i noculation, does not correlale with local reactions at 
1 2  weeks after immunization. 
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Figure 2A: 
Local reaction at injection site caused by 
Miglyol 840 based emulsion, 48 hours 
after vaccination. Predominantly small 
droplets of oil residues are visible 
co-localized with infiltrated 
macrophage-type cells. 
Figure 2B: 
Local reaction at injection site caused 
by Mineral Oil based emulsion, 48 hours 
after vaccination. Large droplets of oil 
residues are visible, co-localized with 
few macrophage-type cells. 
Effect of the type of oil on antibody forming responses 
In the various emulsions examined two types of oil were compared. Marco! 52 is a 
non·metabolizable Mineral Oil containing predominantly Cl4, C l 6  and Cl8 saturated 
hydrocarbons, branched as well as unbranched. Miglyol 840 (Propylene glycol dicaprilate / 
dicaprate), is a metabolizable medium chained triglyceride (MTC), with an average carbon 
chain length of 8 to 10. When comparing otherwise identically composed formulations, 
Mineral Oil-based emulsions tend to promote higher antibody responses than emulsions 
based on Miglyol 840 (Figure 3 and 4). This tendency was more prominent for IBV antigen 
(Figure 4), especially when prepared under low shear (p < 0.05 for all time points, except 
for 3 weeks after immunization), but also for NOV antigen (p < 0.05 for most time points 
(Figure 3). In line with preliminary observations the kinetics of antibody formation also 
seem to differ between the antigens. NOV evokes high responses already at 3 weeks after 
immunization, while IBV responses tend to peak at 6 weeks. These data demonstrate that 
the type of oil used may have bearing on the adjuvanticity of the emulsion. Importantly, 
especially under high shear conditions the water·to·oil ratio in relation to the type of oil 
proved of critical importance as outlined below. 




Effect of water-to-oil ratio on antibody forming responses 
Preparation of a stable W/0 emulsion requires an appropriate composition of the 
water-to-oil ratio, an appropriate emulsifier and adequate shear forces during preparation. 
Especially the choice of an appropriate surfactant is critical, since it is the main factor in the 
emulsification process. In this study a polymeric emulsifier, Arlacel (IC[), was used. 
Preliminary experiments revealed that Arlacel enables the assembly of stable W/0 emulsions 
that contain, relative to the water phase, only very limited amounts of oil phase, i.e. as low 
as 30 %. Despite these high water ratios the emulsions still maintained viscosity features 
suitable for injection (below 250 mPa.s; see table 1 ). Hence, the use of this surfactant 
allowed us to study a wide range of water-to-oil ratios, while preserving other formulation 
parameters. 
As shown in figures 3 and 4, increased Mineral Oil content results in higher antibody 
responses for both high and low shear formulations. This is illustrated by the significantly 
increased NOV-specific antibody responses (p < 0.05, for all time points) evoked by high 
shear, small droplet, Mineral Oil-based emulsions, prepared with high oil content (30:70 
water/oil ratio) compared to the formulation prepared with low oil content (60:40 water/ 
oil ratio). By contrast, for Miglyol -based formulations a high water, low oil, content evokes 
significantly higher NOV antibody titers (Figure 3, p < 0.05 for high shear emulsions at most 
time points and also for low shear, large droplet, formulations at 3 and 6 weeks after 
immunization). Collectively, these data illustrate that the water-to-oil ratio in combination 
with the type of oil used may significantly affect the levels of humoral immune reactions. 
Effect of droplet size on antibody forming responses 
Stability and viscosity of the emulsion, possibly affecting the effectiveness of the 
formualtion, are directly related to droplet size. Apart from the emulsion composition the 
droplet size can be controlled by variations in the method of preparation (see Figure 1 ). 
In this study two preparation methods were investigated, i) emulsions prepared by low 
shear mixing (about 1000 r.p.m.), resulting in low viscosity formulations with a droplet 
size of about I - 40 µm., and ii) emulsions formulated under high shear forces (about 
20.000 r.p.m.). This high shear approach results in emulsions with a droplet size of about 
I µm. All emulsions tested showed no breaking after 3 weeks exposure to 37 °C. Figure I 
shows typical microscopic views of high (Figure IA) and low shear (Figure I B) emulsions. 
No visible discrepancies were noted among high shear emulsions prepared with Mineral oil 
versus Miglyol or distinct water-to-oil ratios tested. Similarly, low shear emulsions gave a 
uniform microscopic view independent of oil type or water-to-oil ratio. 
Figure 3 and 4 show that especially for Mineral oil formulations a larger droplet size (low 
shear preparation) evokes higher antibody responses. This is well illustrated by the the less 
efficacious 60:40 water-to-oil ratio NOV formulation (Figure 3, P< 0.05 for all time points 
tested), but also for the most efficacious 30:70 water-to-oil NOV formulation (Figure 3, 
p <0.05 for all time points, except at 9 weeks after immunization) as well as the 30: 70 
water-to-oil IBV formulation (Figure 4, p < 0.05 for all time points, except for 3 weeks). 
For Miglyol-based formulations low shear emulsions showed superior efficacy compared 
to high shear emulsions for the least efficacious 30: 70 water-to-oil ratio (figure 3, p < 0.05 
for all time points tested). The superior performance of the low shear, large droplet-based 
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emulsions appeared to be compensated for by increasing the water content in high 
shear, Miglyol emulsions or by increasing the oil content in Mineral oil-based, high shear 
formulations as outlined in the previous section. 
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Serological responses to NDV antigen formulated in W/O emulsions, prepared at various water-to-oil ratios, 
distinct shear force and oil type. Statistically significant differences are indicated by symbols with matching 
colours. For clarity reasons only significance between extreme water-to-oil ratios were compared for effect of 
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Serological responses to IBV antigen formulated in W/O emulsions, prepared at various water-to-oi l  ratios, 
distinct shear force and oil type. Statistically significant differences are indicated by symbols with matching 
colours. For clarity reasons only significance between extreme water-to-oil ratios were compared for effect of 
oil type and droplet size. 
Release kinetics study 
To examine a putative correlation between in vivo efficacy and antigen release profiles we 
tested the kinetics of antigen release of the distinct emulsions. In vitro, none of the vaccine 
formulations tested showed any detection of the stable IBDV antigen in the buffer-medium 
over a period of 12 weeks. During this period, no evidence for potential antigen release, 
like breaking or swelling of the emulsions [ 1 5 , 1 6, 1 7], was registered. Reference samples 
showed that the detection of IBDV antigen incubated in buffer medium was not affected 
during this period at 37 ·c. These results show that in-vitro no significant antigen release 
occurred. However, the influence of theoretical degradation of oil or antigens on the antigen 
release kinetics can not be included, since our in-vitro buffer-based system did not contain 
any biological components, like enzymes for instance. 
Discussion 
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In the presen t study we investigated the e ffects of pharmaceutical va riants of W/0 
emulsions, - con taining identical amoun ts of iN DV and i I BV antigen per dose -, on 
imm uniza tion-induced an tivi ra l  an tibody re sponses. Our studies show tha t  the 
compo sition of the adjuvant inco rporated in the vaccine strongly a ffec ts the magnitude 
and dura tion of acquired B cell re sponses to vaccine an tigens. 
Despite recogni tion of the paramount importance of adjuvant choice on vaccine efficacy 
and safety, li ttle i s  known, in gene ral , about the structural requi rements and host 
mechanisms underlying W/0 adjuvant activity [SJ. For W/0 emulsions three major 
mechanisms may be proposed i) W/0 emulsions act as a antigen- retaining depot at the 
injection si te ,  re leasing minute amounts of antigen (signal 1 )  over time [6J, ii) W/0 
emulsions directly attract approp ria te antigen presenting cel ls (APC) to better  provide 
signa l 1 in the lymph node [S], iii ) W/0 emulsions provide direct o r  indirect immune 
response-activating signals (signal 2) to local or recruited APCs [S J. These three paradigms 
are not mutually exclusive as discussed below. 
Our da ta show significan tly highe r immune responses for Mineral Oil-based adjuvan ts, 
especially fo r formulations prepa red unde r low shear condition s, compa red to 
Miglyol-based emulsions. This may be due to a better  depo t effect mediated by Mineral Oi l, 
according to paradigm i). Although i t  was not noted in our in vitro an tigen release study, we 
cannot exclude degradation of oil in vivo resulting in leakage of antigen [ 1  BJ. Biodegradable 
oi ls, such as  Miglyol, are more likely to be degraded by enzymatic reactions, resulting in 
re lease and dispersion of antigens. By contrast, Mine ral Oi l injected in the form of a W/0 
emulsion, show s little dispersion and is not easily deg raded [ 19, 20J. Thi s likely explains 
why residues of the Mineral oi l inoculum are stil l vi sible after 12 week s, even when only 
smal l amounts of oil were used. 
The influence of water-to-oi l ratio on the antibody response to vaccines formulated with 
Mine ral Oil-based adjuvan ts may be rela ted to the viscosity values of the vaccines. An 
increase in wate r- to-oi l ra tio re sul ts in increased visco si ty, which seems to limi t the 
an tibody response fo r both an tigen s fo rmula ted in Mineral Oil emulsions. Vi scosity 
di ffe rences may re sult in va riations of an tigen re lease. However, fo r Mig lyol-based 
formula tions less oil content, is also associated with higher viscosity but results in high 
efficacy. Our da ta show tha t  even wi th comparable viscosi ty levels, and unde r an identical 
formulation composition, a la rge r droplet size i s  associated with higher serum responses. 
This  is evident especia lly for Mineral oil-based emulsions. Theore tically, we cannot exclude 
the possibility that the mixing procedure emp loying high shear forces caused more 
damage to the antigens. Both, NOV and IBV are enveloped viruses and the refore sensitive to 
destruction of B cell epitopes. 
Remarkab ly, while virus-specific circulating antibodies are noted wi thin 3 weeks after 
immunization for N OV and within 6 weeks for IBV, all vaccine formulations tested showed 
no signi ficant antigen release in vitro over a period of 12 weeks. Therefore, instead of being 
released f rom the inoculum, the antigen is most likely taken up wi thin phagolysosomes, 
after endocytosi s of antigen-containing (wa ter-in- ) oil f ragments, by local or recruited APCs 
(paradigm ii). An increase of viscosity may hampe r this  process for Mineral-oil based 






The early local reaction scores at 48 hours demonstrate that an initial, vigorous influx of 
leucocytes, as observed for the Miglyol-based emulsions, is not predictive for high 
antibody responses. Here, non-priming phagocytotic cells may cause a fast removal of 
antigens resulting in impaired immune induction. This may be one of the factors explaining 
why Mineral Oil-based emulsions tend to show higher antibody responses when compared 
to emulsions based on Miglyol 840. The lower efficacy of Miglyol-containing vaccines may 
also result from inappropriate stimulation of APCs by Miglyol oil type relative to Mineral oil 
(paradigm i i i). Possible APC activating effects of lipid mediators present in various oil types 
require further i nvestigations. 
We speculate that the key pharmacophores identified in this study, i.e. the type of oil, 
droplet size and water-to-oil ratio are in  line with paradigms ii) and iii). Early events during 
antigen presentation affect down-stream B cell responses reaching maximum levels within 3 
to 6 weeks after immunization. The typical prolonged duration of antibody titers, observed 
for all formulations tested, is explained by an antigen retaining depot activity of the all 
oil-based e mulsions in  line with paradigm i). 
Collectively, our data suggest that especially variations in water-to-oil ratio in  relation to 
oil-type as well as droplet size are useful for improved antibody i nduction. 
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Abstract 
Structure- and oil type-based efficacy 4 7 
Oil-based emulsions are well-known immunopotentiators for inactivated, "killed" vaccines. 
We addressed the relationship between emulsion structure and levels of in vivo antibody 
formation to inactivated New Castle Disease virus (NOV) and Infectious Bronchitis virus 
(IBV) as antigens in 3 week-old chickens. The use of a polymeric emulsifier allowed for direct 
comparison of three types of emulsions, water-in-oil (W/O), oil-in water (O/W) and W/O-in 
water (W/O/W), while maintaining an identical content of components for each vehicle. 
They were prepared with either non-metabolizable, Mineral Oil or metabolizable, Miglyol 
840. In addition, we assessed the inherent release capacity of each emulsion variant in 
vitro. Remarkably, we noted that W/O type emulsions induced the best immune responses, 
while they released almost no antigen during twelve weeks. In general, Mineral Oil vaccines 
showed superior efficacy compared to Miglyol 840-based vaccines. 
Keywords: oil emulsions, vaccine, antibody responses, adjuvant, release. 
Introduction 
Poorly immunogenic vaccine antigens require an immunopotentiator, or adjuvant, to induce 
the desired type and magnitude of immune response. W/O emulsions have a long history 
and are widely used as immunopotentiating delivery systems for veterinary vaccine 
antigens, notwithstanding their risk for the occurrence of adverse effects at the site of 
injection [ 1). Certain W/O emulsions are currently tested in clinical trials as potentiators 
of therapeutic anti-tumour vaccines [2). An oil emulsion was first used in 19 1 6, for an 
inactivated Salmonella typhirnuriurn vaccine and based on an emulsion of water and 
Vaseline Oil [3). Later Jules Freund developed Paraffin Oil-based emulsions in the absence 
or presence of heat-killed Mycobacteria, called Freund's incomplete and complete adjuvant 
respectively [4). 
These were all water-in-oil (W /0) type of emulsions, composed of antigen-containing 
water droplets (internal phase) trapped within an external, continuous oil phase (Figure I). 
Herbert showed that W/O emulsions retain the antigen at the injection site, allowing a 
sustained release of antigen [5). This persistent release of non-replicating antigens likely 
explains prolonged humoral immunity, caused by provision of antigen to B-cells. However, 
due to high viscosity W/O emulsions are not easy to inject. Moreover, these types of 
emulsion may induce necro-ulcerative lesions at the injection site [6). 
By contrast, oil-in-water (O/W) type emulsions exhibit low viscosity and are generally 
well-tolerated, but induce only short term immune response [7). The antigen is located in 
a water phase that also contains oil droplets. The oil droplets of O/W emulsions may not 
or minimally associate with antigen [8, 9). Administration of O/W emulsion as a particulate 
immunostimulator has been shown to result in recruitment of and interaction with 
antigen-presenting cells at the site of injection. Upon movement towards the draining 
lymph nodes, they increase the efficiency of antigen presentation to T-cells [9). In 
general, the composition of O/W emulsions differs from those of W/O type emulsions. The 
oil content of O/W emulsions is generally lower and O/W production often requires, besides 
special equipment, like high pressure homogenizers, the use of emulsifiers with high HLB 






An intermediate type of emulsion exists as a multiple emulsion or the so-called double 
emulsion. Double (W /O/W) emulsions contain waterdroplets trapped within largeroil droplets, 
which are d ispersed in an external water phase. Antigen may be trapped either within the 
internal water droplets or the external water phase. W/O/Ws may show acceptable adjuvant 
activity and duration with local reactions that are possibly more acceptable when compared 
to those of W/O emulsions ( 1 0] .  However, physical stabi l ity is limited and can only be 
maintained by the use of special polymeric type of emulsifiers [ 1 1 ]. 
Each emulsion type requires a special formulation procedure and suitable emulsifiers. It is 
therefore difficult to relate the adjuvant properties of the emulsion type to a composition or 
structural feature. In the present study we were able to compare vaccine formulations based 
on different emulsion structures using an identical composition of ingredients. W/O, O/W 
and W/O/W emulsions were composed of the same type of oil, a similar oil-to water ratio 
and an identical amount of emulsifiers. For all variants either non-metabolizable Mineral Oil 
or Miglyol 840, a metabolizable Medium Chained Triglyceride, was used. The formulations 
contained the inactivated New Castle Disease Virus (NDV) as antigen, and were administered 
as experimental vaccines to 3 - 4 week-old chickens. Goal of this study was to determine the 
significance of emulsion structure for the efficacy of the vaccine formulation. We conclude 
that all Mineral oil-based formulations showed better efficacy compared to Miglyol-based 
formulations. W/O was superior to W/O/W or O/W adjuvants. However, O/W emulsions 
showed best safety profiles. 
Materials and methods 
Materials 
The oil phases tested were Mineral oil (Marco! 52  from Exxon, USA) and Miglyol 840 (Medium 
Chained Triglyceride from Huls, Germany) and Tween 80 and a polymeric emulsifier, Arlacel 
(both Uniqema, UK), were used as surfactants in all the vaccines. 
Formalin-inactivated New Castle Disease Virus (NDV), strain Clone 30, Infectious Bronchitis 
virus (IBV), strain Massachusetts 4 1 ,  both produced in  eggs, were the viral avian antigen 
examined. The total concentration of virus suspension used was 8 % w/v of the final 
vaccine. Because of its high stability Infectious Bursa! Disease virus (IBDV), strain D78, 
produced in vero cells, was used in similar emulsion variants in order to perform in-vitro 
release studies. The aqueous phase, containing the virus suspension was diluted with 0.0 1 
M Phosphate buffer, pH 7.2. 
Preparation of the emulsions 
Stable and reproducible emulsions were prepared with 0.2 % w/v Tween 80 and 0.5 % w/w 
Arlacel P l 35.  Tween 80 was added to the aqueous phase and Arlacel was mixed into the 
oil phase at 60 ·c. All the inactivated antigen material was part of the aqueous phase. 
The water-to-oil ratio of all emulsions tested was 60 % w/w aqueous phase and 40 % w/w 
oil phase. By using identical emulsion compositions, but different preparation techniques, 
we prepared three d i fferent types of emulsions,  including a water-in-oil  (W /0), a 
water-in-oil-in-water (W/O/W) and an oil-in-water (O/W) emulsion. 
The W/O emulsions were prepared by adding the aqueous phase into the oil  phase, while 
mixing was performed with high shear forces at 20.000 r.p.m. using the Ultra Turrax Type 
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T25 (IKA, Germany). In case of a W/O/W emulsion the water-to-oil-to-water ratio was 30 to 
40 to 30 96 w/w. All the inactivated antigen material was added to the inner aqueous 
phase. The preparation was performed in two steps. First, the primary W/O emulsion was 
prepared as described above. The obtained W/O emulsion was then mixed into the secondary 
aqueous phase at 1 000 r.p.m. using the Eurostar mixer (IKA, Germany) provided with a 
propeller blade. 
The production of the O/W emulsion required the use of a high pressure homogenizer 
(Microfluidizer type M-1 20 E; Microfluidics, USA). A premix was prepared by adding a part of 
the oil phase to 0.01 M Phosphate buffer, pH 7.2. This premix was subsequently microfluidized 
at a pressure of 800 - 850 bar. All the inactivated antigen material was added. Finally, the 
remainder of the oil phase was added using the Ultra Turrax Type T25 at 1 1 .000 r.p.m. 
Figure 1 :  
Microscopic view (magnification 1 000x) of prototypic emulsion structures: (A) W/O; (B) W/O/W; and (C) O/W. 
The droplet size of the emulsions was determined by interference microscopy at l 00Ox 
magnification (Olympus, model BXS0, Japan). Accelerated physical stability tests were 
performed by determining the appearance and microscopic view after storing at 3 7 'C for 
three weeks. Microscopic examination confirmed that the different types of emulsions were 
produced as expected. Microscopic view was also used to determine the droplet size of 
the emulsions. Only small differences in droplet size were observed between the Mineral 
Oil- and Miglyol 840-based emulsions (Fig. 1 ). All emulsions proved physically stable during 
three weeks at 3 7 ·c. 
Immunization of animals 
Groups of three-to-four week-old specific pathogen free (SPF) female White Leghorn 
chickens (n = 8 - 1 0) were vaccinated (0.5 ml/dose), in the breast muscle. Blood samples for 
serological tests were taken at weeks 3, 6, 9 and 1 2  after vaccination. Virus neutralization 
tests specific for IBDV were performed to determine the levels of antiviral serum antibody 
titers. 
During the course of the experiment all animals immunized with various emulsion vaccines 
appeared healthy without notable clinical symptoms. Local reactions at the injection site 
were monitored at 1 2  weeks after vaccination. 
Assays for serum antibodies 
Serum levels of NDV-and IBV-specific antibodies were determined by a standard 
haemagglutination inhibition (HI) assay. Serial two-fold serum dilutions were prepared i n  






units/ 50 µI NOV or IBV antigen. 2Log titers were expressed as the reciprocal of the highest 
dilution that gives complete inhibition of haemagglutination. Samples were regarded to be 
positive at an inhibition of haemagglutination at dilution .!: 1: 2 (NOV) (2log2) and 1: 16 (IBV), 
respectively. 
Kinetics of antigen release 
Inherent antigen-release characteristics of the various formulations were determined in  
release kinetics studies, performed i n  vitro. The different vaccine-formulations contained 
inactivated Infectious Bursa! Disease Virus (IBDV) strain D78, produced on Vero cells, at a 
concentration of 1000 ELISA-units/ml. IBDV belongs to the family of Birnaviridae. To 
simu late in vivo conditions, 5 ml of these IBDV-vaccines were mixed in 15 ml isotonic 0.01 M 
Phosphate buffer, pH = 7.2 and placed at 37 ·c while stirring. Samples were taken at 
different time points from the buffer-medium over a period of 12 weeks. A filter was used 
to exclude emulsion-droplets in the sample. The removed buffer medium was replaced 
immediately by fresh medium. 
Determination of the antigenic mass of IBDV in the samples was performed by R-63-ELISA. 
Wells of polystyrene microtiter plates, coated with neutralizing monoclonal antibody R-63 
were fil led with sample and reference antigen in serial dilutions. Biotin-labeled antibody 
(R-63-biotin) was used to detect IBDV antigen captured by the coated antibodies. Antigen 
release was expressed as percentage of total antigen content incorporated in the vaccine 
formulation at t = 0. 
Statistical analysis 
Comparison of means of serum titers was performed using analysis of variance (ANOVA) 
with least significant difference (LSD) as multiple comparisons test. All  results were 
generated using SAS (version 8.2) software. Differences were considered significant if Pwas 
less than 0.05. 
Results 
In vitro results 
Study of the microscopic view confirmed that the different types of emulsions were 
produced as expected. Microscopic view was also used to determine the droplet size of the 
emulsions (Fig. 1). Only small differences in droplet size were observed between the Mineral 
Oil- and Miglyol 840-based emulsions (table I). All emulsions proved physically stable 
during three weeks at 3 7 ·c. 
Emulsions based on Mineral Oi l  Emulsions based on Miglyol 840 
Water-in-oil type mainly l - 1 0 µm mainly l - 10  µm 
of emulsion 
Oil-in-water type l 00 % smaller than 200 µm,  l 00 % smaller than l 00 µm,  
of emulsion about 50 % between l - 3 µm about 50 % between l - 3 µm 
Water-in-oil-in-water primary emulsion: 1 -5 µm, primary emulsion: 1 -5 µm, 
Type of emulsion secondary emulsion: secondary emulsion: 
mainly l O - 50 µm mainly 5 - 40 µm 
Table 1 :  Droplet size of  various types of  emulsion based on Mineral Oil or Miglyol 840. 
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The in-vitro antigen release experiments showed differences between the emulsion types 
(Fig. 2). The 0/W type of emulsion showed no detectable antigen absorbance features, 
for both oil types. However, the release kinetics of the W /0 emulsion type, were 
remarkable. During twelve weeks no antigen release was detected at any point 
in time for both Mineral and Miglyol oil emulsions. The kinetics of antigen release of 
the W/0/W emulsions proved somewhere between those of the W/0 and 0/W 
emulsion, for both oil-types. The Miglyol 840 based emulsion showed a lower release level 
compared to the Mineral Oil-based W/0/W emulsion (Fig. 2). During the twelve week period, 
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Figure 2 :  
Antigen release b y  prototypic emulsion structures in vitro. Distinct emulsion structure formulated with 
Mineral oil (top) or Miglyol oil (bottom) release IBDV antigen in vitro with different kinetics. Data are ex­
pressed as mean percentage of total antigen content incorporated in the vaccine formulation at t = 0. 
The types of emulsion are varied: 
• :  water-in-oil emulsion, • : water·in·oil·in-water emulsion, .a.: oil-in-water emulsion. 
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In vivo results 
Effects of distinct emulsions on local reactions 
At 1 2  wee ks after inoculation local reac tions at the injection site were monitored by 
post-mortem macroscopic inspection. Miglyol 840-based vaccines showed no local 
reactions at all, nor any vaccine residues, except for the W /0 type of emulsion, which 
showed some traces of the inoculum (data not shown). In contrast, all the vaccines 
containing Mineral Oil showed moderate local reactions (not shown). 
Effects of distinct emulsions on antibody forming responses 
Both the type of oil and the formulation struc ture proved to cons iderably affect the 
antiviral antibody for ming responses against N DV and IBV, respect ively ( Fig. 3 and 4). 
In general, when co mparing identical types of e mulsions, v accines containing Mineral 
Oil evoked higher H I  antibody responses to both viral antigens than Miglyol 840-based 
emulsions ( Fig. 3 and 4). For Mineral oil-based formulations W /0 showed statistically 
superior i mmunization efficacy when co mpared to 0/W - except for wee k 15-, while 
W /0/W showed intermediate efficacy. For Miglyol-based v accines a si milar pattern w as 
noted (Fig. 3 and 4). This was noted for both antigens, with I BV exhibiting less 
i mmunogenicity than N DV ( Fig. 3 and 4). 
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Serological responses (HI-titers) of NDV vaccines based on distinct emulsions containing A) Mineral Oil, or 
B) Miglyol 840. Statistical analysis revealed significant differences between mean titres (n = 8- 1 0) ± SD of al l  
groups at each time point, except for: 
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Figure 4: 
Serological responses ((HI-titers) of IB·M41 vaccines based on distinct emulsions containing A) Mineral 011 or 
BJ Miglyol 840. Statistical analysis revealed significant differences between mean titres (n = 8· 1 OJ ± SD of all 
groups at each time point, except for: 
graph A: all groups at time point: 3 weeks 
• and • at time points: 3, 6 and 1 2  weeks 
• and • at time point: 1 5  weeks 
graph B :  all groups at time point: 3 weeks 
• and • at time point: 1 5 weeks 
• and • at all time points 
From these  experiments we conclud e  that structural differences betw een emulsion 
types, composed of identical ingredients, can affect humoral immunity to the formulated 
antigen. However, the structure-related immunization efficacies are inferior to the 
typ e of oil used in th e formulation; an O/W formulation based on Mineral oil showed 
an efficacy similar to th e best p erfoming Miglyol-based W /0 formulation for both viral 
antigens. 
Discussion 
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We succeeded in preparing structurally distinct types of oil-based emulsion vehicles 
without adapting the chemical composition of the vaccine. The distinct formulations 
based on identical ingredients allow direct evaluation of effects of emulsion structure 
significance, and consequently antigen localization within the formulation, on biological 
efficacy. 
For W/0 emulsions our results show an inverse relationship between antigen release levels 
and the height of the in vivo antibody responses. In general, the immunopotentiating effect 
of W/0 is superior to that of 0/W or W/0/W. Given that B cell priming requires recognition 
of free antigen fragments by surface-bound immunoglobulin receptors, it is remarkable that 
the W/0 type of emulsion evoked the highest immune response, while retaining antigens 
for a period of more than twelve weeks in vitro. One might, therefore, conclude that delayed 
release features of a vaccine formulation are responsible for improved antibody responses; 
the sustained presence of antigen would favour humoral immune responses [5, 1 2, 1 3). 
Possibly, the release of minute amounts of antigen actually occurs in vivo, while our in vitro 
release studies fail to mimic this situation. For example, an enzymatic, lipase-containing, 
environment at the injection site, or draining lymph node may result in degradation of oils. 
Post-injection metabolism of biodegradable Miglyol 840 is anticipated. Nevertheless, in that 
case only non-detectable, minute amounts of antigen would suffice to evoke high antibody 
titers when administered in the context of W/0 formulations. By contrast, high doses of 
antigen released in the context of an 0/W formulation evoke humoral responses inferior 
to those triggered by W/0-antigen formulations, despite instant availability of almost all 
antigen and co-localization of identical adjuvant components at the injection site. However, 
desorption of the antigen into interstitial fluid may not at all be necessary for W/0 
emulsions to act as immunopotentiators for antigen-specific T cell help. Following augmented 
APC recruitment, up-take of antigen may occur only within phagolysosomes after endocytosis 
of antigen-containing W/0 fragments. Hence, prolonged localization of the antigens at the 
injection site might be the main advantage of the W/0 type of emulsion compared to 0/W 
or W/0/W types. 
0/W and W/0/W release higher doses of antigen and may recruit other or less relevant 
antigen-presenting cells [9) with reduced immunopotentiating activity, for example due to 
less efficient up-take, processing or presentation of antigen. Similarly, studies of efficacious 
aluminium adjuvant-containing vaccines showed no need for antigen adsorption [ 14). 
Dissection of the exact immunological mechanism of immunopotentiation remains subject 
for further studies. Both, W/0 emulsions, -including the prototypic Mineral oil-based 
incomplete Freund's adjuvant (IFA)-, as well as 0/W emulsions, such as MF-59, recently 
proved to evoke type I interferon (IFN) as an essential mediator of in vivo immunopotentiation 
[ 1 5), as determined in gene-deleted hosts. Differences in IFN inducing capacity may explain 
the observed efficacy differences in our experiments. 
Remarkably, when using Mineral oil the least effective 0/W formulation proved equally 
effective when compared to the best performing W /0 formulation containing Migl yo I. Hence, 
in vivo efficacy is dominated by the type of oil more than the emulsion type. 
When studying a variety of animal, vegetal and synthetic oils, Stone found comparable 
results for oil-based emulsions carrying NDV as antigen [ 1 6). For the W/0 type of emulsion 
and, also the W /0/W emulsion, to a certain extend, this may be explained by the 
"' ... 
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non-biodegradability o f  Mineral Oil, resulting in the establishment o f  a persistent 
antigen-containing nidus at the injection site. However, the stronger immune response 
evoked by the Mineral Oil based O/W emulsion compared to the Miglyol 840 based O/W 
emulsion cannot be explained by this theory. Possibly, lipid substances or oil droplet 
moieties represent immunostimulatory ligands able to alert the immune system. Dresser 
showed immunopotentiation for an otherwise poorly immunogenic intravenously injected 
soluble protein by a Freund's adjuvant formulation, made up without antigen, when the 
emulsion was given at a distant subcutaneous site ( 1 7). The sensors for these ligands are 
undefined. Adjuvant features of saturated straight-chained hydrocarbons of C-15  to C-20, 
normally found in refined Mineral Oil have been described by Shaw et al. (1 8). The absence 
of reactive groups in Mineral Oil may also protect antigens from denaturation when 
interacting with the oil phase. Zelisko et al showed that proteins residing at the interface of 
inert Silicone oil emulsions are stabilized against denaturation ( 1 9). 
In conclusion, assessment of different types of emulsion vehicles, using the same 
chemical composition, revealed an inverse relationship between antigen release and 
antibody response for W/O emulsions. W/O emulsions induced the highest antibody 
response, more than W/O/W or O/W. W/O type of emulsion keep antigens localized at 
the injection site, which are likely liberated after endocytosis of emulsion fragments by 
recruited APC's. In all types of emulsion vehicles tested, Mineral Oil-based emulsions show 
superior antibody responses compared to emulsions containing Miglyol 840. 
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Summary 
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The release requirements for vaccine antigens (Ags) delivered by adjuvants with presumed 
depot function are poorly understood. Water-in-oil (W/0) emulsions are routinely used in 
many poultry vaccines. They strongly activate antibody production, and are regarded as a 
depot from which Ags are slowly released, resulting in prolonged antigen residence. 
However, from earlier studies we concluded that W/0 adjuvant activity is partly based on 
the immunostimulatory activity of the oil phase. Here we assessed the dose and regimen 
requirements for viral antigen in immunization experiments in chickens. Three-to-four 
week-old White Leghorn chickens were repeatedly injected with inactivated antigen of 
infectious bursa! disease virus (IBDV) during 48 days. Our aim was to compare the 
antibody responses in repeatedly injected animals, receiving fractioned doses of antigen, to the 
responses in animals receiving only one injection of the full dose of Ag formulated in either 
a W/0 emulsion or in saline. We observed that repeated administration of small amounts 
of Ag results in a gradual increase of specific humeral immune responses during the 
immunization regimen. Immunization with a higher first dose evoked an early higher 
antibody response, which however, reached a similar plateau level at the end the 
regimen. When compared to lower first dose regimens a slow decline of serum antibody titer 
following two weeks after arrest of Ag injections indicated that repeated injection of small 
doses of Ag indeed mimic the efficacy of depot-forming adjuvants. All regimens of 
fractioned antigen in saline, however, proved less effective, when compared to a single dose 
vaccination of the cumulative amount of antigen formulated in a W/0 emulsion. From our 
data we confirm that W/0 emulsions are very effective vaccine vehicles for improving 
antigen-specific humeral responses in chickens, due to a combination of antigen residence­
prolonging activity and direct immune stimulation. 
Introduction 
Incorporation of Ags into the aqueous phase of a water-in-oil (W/0) emulsion as a means of 
immunopotentiation was initially discovered in 1916, when Le Moignic and Pinoy 
vaccinated mice with inactivated Salmonella typhimurium in an emulsion of water and 
Vaseline oil (Le Moignic, 1 9 16). Broad introduction of W /0 emulsions followed in 1 93 7 by 
Freund. W/0 emulsions are known to strongly activate antibody production. This is partly 
based on the immunostimulatory activity of the oil phase. A range of lipoid substances like 
hexadecane, squalene, methyl oleate or pristane, possesses adjuvant activity for a variety of 
antigens (Freund, 1951; Whitehouse et al., 1 974). Especially non-metabolizable Mineral oil, 
the lipoid substance of Freund's W/0 emulsion shows strong immunopotentiating activity. 
When comparing identical emulsion compositions, varying only in the type of oil, 
non-metabolizable Mineral oil generally evokes higher antibody responses than biodegradable 
oil, such as a Medium Chained Triglyceride Uansen et al., 2005; Jansen et al., 2006). 
Immune activation by W/0 emulsions is likely based on triggering of an inflammatory 
response at the injection site that leads to attraction and activation of antigen presenting 
cells (APCs) by provision of critical immune responses activating signals (Dupuis et al., 
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shown that Toll-l ike receptors are not the essential receptors to trigger antibody responses 
where classical adjuvants such as Freund's or alum are concerned (Gavin et al., 2006). Apart 
from these direct immunostimulatory effects W/O emulsions are regarded as antigen (Ag) 
delivery systems. They are assumed to act as an inert depot from which the emulsified Ag 
is slowly released for a prolonged period of time to supply the site of antibody production, 
a process which is considered to be a crucial factor in maintaining immune responses. 
Indeed, W/O emulsions show depot characterist ics for incorporated Ags, because in this 
two-phase emulsion system the Ag-containing aqueous phase is dispersed as small droplets 
in the continuous oil phase. By contrast, oil-in-water (O/W) emulsions, with the Ag-containing 
water phase as the continuous phase, show a different release profile of formulated 
antigen. After minimal or no delay it is quickly released (Aucouturier et al., 2001 ;  Jansen et 
al., 2006). 
In 1968 Herbert published an elegant s tudy on the mode of action of W/O emulsion 
adjuvant for antibody production in mice (Herbert, 1968). Using highly-purified ovalbumin 
(OVA) in Mineral Oil emulsions, he came to the following conclusions. Firstly, high antibody 
responses were observed in mice inoculated with even the smallest quantity of OVA in W /0 
emulsion; dilution of W/0 emulsions with more oil seems to increase the init ial antibody 
formation. Secondly, no adjuvant effect was observed in case of the sole presence of 
emulsifiers that are used in the formulat ion of W/O emulsions. In addition, residual W/O 
emulsion depots, found encapsu lated at the injec tion s ite in mice at 2 7 1  days af ter 
inoculation, when collected and administered subcutaneously into naive mice, contained 
sufficient Ag to st imulate an antibody response in these newly inoculated mice. This 
suggested that not all Ags are released from the inject ion site during the period of 27 1  days. 
Herbert at tempted to mimic a slow release mechanism by daily injections of t iny doses of 
OVA alone in mice (Herbert, 1966) and noted an ant ibody production profile similar to a 
single full dose OVA formulation in W/O emulsion. Interestingly, the antibody level in the 
circulation dropped soon after the daily injections were stopped. 
The present s tudy revisited the dose and regimen requirements for viral Ag in chickens, a 
species rout inely immunized with W /0 emulsion vaccines in the poultry industry. 
Three-to-four week-old birds were repeatedly injected with inactivated antigen of infectious 
bursa! disease virus (IBDV) during 48 days. Our aim was to compare the antibody responses 
in repeatedly injected poultry, receiving fract ioned doses of antigen, to the responses of 
animals receiv ing only one injection of the full dose Ag, formulated in ei ther a W/O 
emulsion or in sal ine. Apart from a regimen of fractionated, repeatedly administered, 
constant Ag doses, we also examined multiple injections of variant Ag dose-strength for 
their capacity to elicit Ag-specific antibodies. 
We conclude that a combination of both Ag depot activity together with direct immune 
st imulation makes W/O emulsions very effective vaccine vehicles for augmenting humoral 
responses in chickens. 
Materials and methods 
Preparation of vaccines. All Ag formulations contained formalin-inactivated Infectious 
Bursa! Disease Virus (IBDV) strain D 78. Vaccine Ags used for repeated injection were merely 
diluted with 0.01 M Phosphate buffer, p H  7.2 without addition of any immunopotentiating agent. 
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One emulsion was prepared using Mineral Oil (Marco( 52 from Exxon, USA) as oil phase. The 
W/O emulsion was prepared by adding the aqueous phase into the oil phase, while mixing 
was performed with high shear forces at 20,000 r.p.m. using an Ultra Turrax Type T25 ((KA, 
Germany). The aqueous phase, containing the virus suspension was diluted with 0.0 1 M 
Phosphate buffer, pH 7.2. 
Immunization of animals. Groups of three-to-four week-old specific pathogen free (SPF) 
female White Leghorn chickens (n = 8 - 10), housed under clean conditions with access to 
water and standard commercial food ad libitum, were used for immunizations. In case of 
repeated administration, a 0. 1 ml/dose was administered by immunizations in the left and 
right breast muscle, respectively, every other day, for a period of 48 days. Two groups of 
chickens received a series of repeated vaccinations. One group obtained a constant dose 
IBDV of 4 units during 25 administrations (group 1), and the other group a decreasing dose 
during the first 4 administrations at a rate of 3 1  - 15 - 8 - 4 units/dose (group 2). 
The 5th - 25'h administration contained 2 units/ dose (table 1 ). The total cumulative amount 
of Ag administered in both series of repeated injection is 100 units. Three reference groups 
were included in this study. One group received a single dose of an inactivated IBDV vaccine 
of 100 units formulated in the W /0 emulsion (group 4), while the second reference group 
received a single dose of 100 units IBDV diluted with 0.01 M Phosphate buffer, pH 7.2 (saline; 
group 3). In case of a single dose injection, chickens received 0.5 ml in the breast muscle at 
time zero. In addition, one group received only 2 units Ag in W/O emulsion (group 5). 
Day 0 Day 2 Day 4 Day 6 Day 8 Day Total Vehicle 
1 0-48 amount of 
antigen 
Group 1 4 units 4 units 4 units 4 units 4 units 20 X 4 1 00 units saline 
units 
Group 2 31 units 1 5  units 8 units 4 units 2 units 20 X 4 1 00 units saline 
units 
Group 3 100 units - - - 1 00 units saline 
Group 4 100 units - - - 1 00 units w/o 
emulsion 
Group 5 2 units - - - 2 units w/o 
emulsion 
Table 1 :  Amounts of antigen administered during the study. 
To investigate immunopotentiating effects of repeated injections one special reference 
group was added to the experiment. This group received at time zero 100 units IBDV diluted 
with 0.0 1 M Phosphate buffer, pH 7.2 in a 0.1 mo! dose, followed by 24 injections of placebo 
0. 1 ml of Phosphate buffer, every other day, for a period of 48 days. 
Blood samples for serological tests were taken at weeks 3, 6, 9, 12, 15 and 1 8  after vaccination. 
Also blood samples were taken at week 7, the time point of the final administration of the 
repeated injection series. 
Local reactions at the injection site were monitored at 18 weeks after vaccination. All 
experiments were approved by an independent Animal Welfare and Ethical Review Committee 






Assays for serum antibodies. Serum levels of IBDV- specific antibodies were determined 
by virus neutralization assay. Serial two-fold serum dilutions were prepared in microtitre 
plates and mixed with an equal volume containing 650 TCID50 / 1 00 µl of IBDV. After 
pre-incubation, Chicken Embryo Fibrolast (CEF) cells were added. For at least 5 days the 
cells were cultivated and then examined for the presence or absence of typical cytopathic 
effect (cpe). The titers of the test samples are expressed as means (2log) of the reciprocal of 
the highest dilution where all virus was neutralized. 
Statistical analysis. Comparison of means of serum titers was performed with one-way 
analysis of variance (ANOVA) by comparing time point values between groups and by group 
analysis between time points (GLM) with least significant difference (LSD) as multiple 
comparisons test. All results were generated using SAS (version 8.2) software. Differences 
were considered significant if P was less that 0.05. 
Results 
Safety of experimental procedures. During the course of the study all immunized animals 
appeared healthy without notable clinical symptoms, although some immunization groups 
may have been "stressed" - to a limited extend - by injections every other day during a 
period of 48 days. 
Local reactions at the injection site were monitored at 1 2  weeks after vaccination. Only the 
vaccine based on W/0 emulsion showed residues of the inoculum as expected (data not 
shown). 
Effects of distinct antigen administration schemes on specific antibody formation. Results 
of the immunization efficacies measured as circulating virus-neutralizing antibody titers in 
time after immunization are shown in figure 1. 
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Figure l :  Serological responses expressed as group means of virus-neutralizing antibody titers (21og) 
specific for IBDV.Arrow indicates arrest of repeated antigen administration.Statistical analysis revealed 
significant differences ( p < 0.05) at time points indicated in table 2 .. Statistical analysis within groups 
between time points revealed no significant differences for any group, except for group I between week 3 
and 9 and week 3 and l 8, as well as within group 5 between week 7 and l 5 and week I S and l 8. 
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Statistical comparison between groups: 1 -2 1 -3 1 -4 1 -5 2-3 2-4 2-5 3-4 3-5 4-5 
3 weeks after vaccination * * * . * * * . * * 
6 weeks after vaccination * * * * * * . * * 
7 weeks after vaccination . * * * * * * * 
9 weeks after vaccination * * * . * * • * * 
1 2  weeks after vaccination * * * . * * * * . 
l 5 weeks after vaccination . * * * * * * . . 
1 8 weeks after vaccination * * * * * * . . 
• Significant difference (P < 0.05); -, no difference between groups 
Table 2 :  Statistically significant differences (P < 0.05) between groups at different time points. 
Repeated injection of a constant, small dose of inactivated IBDV antigen (4 units), -every 
second day, over a period of 48 days (group 1 )·, evoked antibody responses that gradually 
increased over time. The rise in serum titers continued for two weeks after the arrest of 
antigen injections. Repeated injection of decreasing amounts of antigens (group 2), i.e. an 
initial high dose, followed by a gradual dose decline is more efficacious, when compared to 
repeated administration of identical Ag amounts of 4 units (group 1). After arrest of antigen 
injections the gradual decline in antibody titer is similar between both groups. Administration 
of a single full antigen dose ( 1 00 units) in saline buffer at time zero evokes a more effective 
humoral immune response detectable at 3 weeks after immunization with a slow decline in 
antibody titers during 18 weeks of measurement (group 3). 
To examine potential immunopotentiation as a result of local "danger" signals resulting 
from theoretical injection trauma at the site of inoculation, we tested the effect of repeated 
saline (placebo) injections after a full dose (100 units) at day O and in another group after a 
minimal single dose of 2 units. It proved that additional administration of saline (placebo) 
injections every other day during a period of 48 days, stimulated no increase in antibody 
response, when compared to a single injection of 100 units of Ag (data not shown). A single 
injection of 2 units followed by repeated injections of saline on every other day gave no 
measurable titer (data not shown). Even when formulated in W/0 emulsion 2 units of Ag 
failed to induce a detectable antibody titer (group 5). However, the same W/0 formulation 
improved antibody titers, approximately 4-fold ('log 2) for 100 units of Ag (group 4), when 
given as a single shot at day 0. Interestingly, after about 7 weeks the kinetics of the serum 
antibody titer is comparable to the single dose administration without immunopotentiator 
and resembles the profile noted in an earlier study (Rijke et al., 1995). Notably, statistical 
analysis revealed no significant differences in the kinetics of circulating antibody titers 
between groups immunized with Ag in saline only, including those receiving fractioned Ag 
dosing, at 6 weeks after primary immunization and later time points until the end of the 
experiment. However, data from Figure 1 suggest that Ag dose (high versus low) determine 
acceleration / kinetics of the antibody response from O - 3 weeks, whereas Ag potentiated 
by the W/0 emulsion affected the magnitude but not kinetics. This suggests the importance 
of the adjuvant not in the form of a depot, but to function in an as yet to determine 
facilitating fashion, for example increasing the number of activated B cells. 
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We conclude that repeated administration of small a mounts of IBDV Ag results in a gradual 
increase of specific humoral immunity in White Leghorn chickens, a lthough less effective 
when compared to a single dose vaccination of the same amount of Ag formulated in a W/O 
emulsion. The in-vivo data of this experi ment were in line wi th those of a si mi lar 
experi ment in SPF White Leghorn chickens performed earlier (data not shown). 
Discussion 
The requirements for vaccine Ag release from depot type delivery syste ms are poorly 
understood. Purpose of the present study was to obtain more information on the importance 
of a slow Ag release mechanism for induction of antibody responses in chickens. 
We therefore initiated investigations on the relationship between dose and time of in vivo Ag 
availability and specific antibody formation. Earlier studies of Herbert indicated that antibody 
responses obtained by injection of very small daily doses of Ag in mice could mimic the 
effectiveness of depot-forming adjuvants like W/O emulsions (Aucouturier et al., 2001). 
Indeed, in our study we also found stimulation of the antibody-forming cells and a gradual rise 
in circulating antibody titers in White Leghorn chickens by repeated injection of tiny quantities 
of Ag. However, both the onset and the magnitude of antiviral antibody titer was less pronounced 
when compared to those a fter injection of a full dose formulated in a W/O emulsion. 
Our results are not completely in line with the findings of Herbert. The peak antibody 
response obtained by repeated injections was never as high as the antibody level obtained 
by a single administration of a full Ag dose in a W/O emulsion or in saline alone. We used 
a two day time-interval between the administration of Ag, which was given in the left and 
right breast muscle in an alternating injection schedule, instead of Herbert's daily dose 
regi men given subcutaneously. A lso, we measured responses in poultry, while Herbert studied 
responses in mice. In addition, IBDV antigens in saline alone are capable of inducing high 
antibody responses, because virus particles with repetitive structures are more immunogenic 
when compared to ovalbumin (Bachmann et al., 1993; Jegerlehner et al., 2002; Wit de et al., 
2004). 
Notably, the immunogenicity of the viral Ags proved dependent on the concentration of 
inactivated virus par ticles at the injection site following the first injection. The initial 
amount of IBDV in the repeated low dose (4 units) schedule was probably too low to induce 
prompt antibody formation. Repeated injections starting with a higher dose of 3 1  units 
were more efficacious, and just one dose of 100 units was most effective in antibody 
induction. A higher initial dose resulted in an earlier peak of antibody titers. However, at 
6 weeks after primary immunization and at later time points no statistically significant 
differences between the levels of serum antibody titers were noted between these groups. 
In general, Ag availability is considered necessary for the maintenance of Ag-specific 
antibodies in the circulation for a prolonged period of time. It is debatable whether Ag 
availability can only be achieved by prolonged or pulsed release of free Ag. Oil-based vaccines 
are very effective in maintaining Ags at the injection site. In vitro release studies of several 
W/O type of emulsions showed no detectable release of Ags during the first 3 weeks of 
measurement (Aucouturier et al., 2001;  Jansen et al., 2005; Jansen et al., 2006). Hence, the 
importance of a depot of a high concentration of stable Ags a t  the injection site should not 
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be underestimated. As soon as Ag-specific antibodies have been formed, the sustained 
presence of Ag in draining lymphoid organ and at the injection site is likely an important 
factor for the duration of the response. 
However, since initiation of adaptive immune responses takes place in lymphoid organs, 
Ags need to be translocated from the site of injection towards the local lymph node or the 
spleen, where interaction with adaptive T- and B cells allow the completion of T cell dependent 
B cell responses (Flarend et al., 1 997). Jenkins et al describe this translocation of Ags in 
mice as two waves of antigen influx. The first Ag influx is based on intact Ags that reach 
the T cell zone in the lymph node early after injection. The second wave of Ag influx occurs 
within 24 hours after injection and is based on Ag-presenting dendritic cells at the injection 
site that contain processed Ag and move towards the nearest draining lymph node via 
afferent lymphatics Otano et al., 2003) . This suggests that a period of about one day of Ag 
persistence may be sufficient to evoke an augmented level of antibody production. This may 
explain the activity of depot-type delivery systems such as W/0-based emulsions and 
aluminium. Flarend et al. ( 1 997) demonstrated that Aluminium salts already start to 
dissolve within one hour after injection. Aluminium salts may maintain Ag at the site of 
injection for a relatively short, but sufficient period of time. 
Freund studied the role of the depot function in rabbits, by measuring antibody 
formation after surgical removal of the vaccine from the site of injection. Excisions 
performed between 30 minutes and four hours after injection resulted in a decrease of the 
immune response when compared to the response in animals in which the injected areas 
were not removed. However, excisions performed after one or more days did not seem to 
affect the antibody response (Freund, 1 9 5 1  ). 
W/0 emulsion-based vaccines effectively maintain Ags at the injection site, enabling 
injection of less amount of Ag when compared to non-adjuvanted vaccines, which makes 
them attractive vaccine vehicles from an economical point of view for the poultry industry 
(Aucouturier et al., 2001 ). The observed immediate improvement of the overall magnitude of 
antibody titers by W/0 emulsions early after immunization, when using a constant amount 
of Ag, indicates that W/0 emulsions also act as direct immune system activating immuno­
potentiators, which may vary in efficacy depending on the type of oil used Uansen et al., 
2005). The emulsion structure or carbohydrate molecules may facilitate -directly or through 
release of local mediators - the recruitment of the desired type of antigen-presenting cells 
(APC). Uptake of Ag by recruited APC may occur after endocytosis of Ag-containing W/0 
fragments, since very little antigen is released from the W/0 depot in vitro and likely in vivo 
(Aucouturier et al., 2001 ;  Jansen et al., 2005 ;  Jansen et al., 2006). 
In conclusion, a combination of both prolongation of Ag residence together with direct 
immune stimulation makes W/0 emulsions very effective vaccine vehicles to improve 
Ag-specific humoral responses. The critical spatio-temporal characteristics of the release of 
free Ag from the depot at the injection site remains to be defined (Schijns, 2000) and has to 
be studied in more detail. 
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Summary 
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Water-in-oil (W/0) emulsions act as vaccine antigen vehicles and strongly promote specific 
antibody production. These formulations are considered as a depot from which antigens 
are slowly released, resulting in prolonged antigen residence time. However, local side reactions 
and residues represent safety concerns for these vaccine formulations. 
In this study we examined the effect of dosage-volume on efficacy and safety of vaccines 
based on W/0 emulsions. Minimizing dosage volume could possibly minimize local 
reactions at the injection site, which would improve prospects for W/0 emulsions as 
vaccine-vehicles. Mineral oil-based W/0 vaccines, containing a combination of inactivated 
antigens of infectious bronchitis virus and Newcastle disease virus were administered 
intramuscularly to 3 - 4 week-old chickens with dosage-volumes of 0,5 ml or 0.25 ml, both 
containing the same amount of antigen. Also the efficacy and safety of infectious bursa! 
disease vaccines, at I 00 units per dose in W /0 emulsions, were examined in chickens at 
dosage-volumes of 1 .0 ml, 0.5 ml, and 0.05 ml. 
Our results reveal that the range of dosage volumes tested did not significantly influence 
the serological responses for all types of antigens studied. However, decreasing the dosage 
volume appeared to minimize local reaction scores. Hence, minimizing the dosage-volume 
of W /0 based emulsion vaccines might make this type of vaccine-vehicle even accessible to 
human vaccination program. 
Introduction 
For several decades water-in-oil (W/0) emulsions have been used In a wide variety of 
inactivated veterinary vaccine formulations. W/0 emulsions are regarded as antigen (Ag) 
delivery systems. They are assumed to act as an inert depot from which the emulsified 
antigen is slowly released over a prolonged period of time to supply the site of antibody 
production, a process which is considered to be a crucial factor in maintaining immune 
responses [I , 2). Indeed, W /0 emulsions show depot characteristics for incorporated 
antigens, because in this two-phase emulsion system the antigen-containing aqueous phase 
is dispersed as small droplets in the continuous oil phase. 
When suspended in aqueous media the antigen material is mostly located in the water 
phase. Since this water phase is dispersed in the oil phase, antigen material is trapped and 
is not immediately available after inoculation. Therefore, W/0 emulsions characteristically 
retain the antigen at the site of injection, thereby displaying a depot function and, hence, 
protecting the antigen from rapid release and degradation (3). 
According to the geographical concept and depot theories [ 1, 2, 4,), the sustained release 
of antigen may facilitate signal I expression in secondary lymph organs and is essential 
for durable immune response [SJ. Especially the rate of antigen release from the injection 
sites is assumed to be a crucial factor in maintaining antigen-specific immune responses 
(6). Many vaccine formulations are able to delay release of antigens, yet the critical 
characteristics of an antigen release profile necessary to evoke an efficacious immune 
response is unknown. Alternatively, liberation of antigen or its fragments may occur 
only within the phagolysosome after endocytosis of W/0 fragments by recruited antigen 
presenting cells. However, the trigger for recruitment, if existing at all, is unknown. 




It has been well established that only small amounts of the injected antigen eventually 
reaches the adaptive immune cells (3). In the same study, it has a lso been shown that the 
antigen concentration influences the antibody titer (3). 
However, although the antigen concentration does not play a significant role, apart f rom 
the need of a minimal concentration for reaching a threshold response, it remains to be 
determined whether the dosage volume plays a role in affecting a given antibody titer level. 
Especially for vaccines based on W/O emulsion, reduction of dosage volume cou ld be of 
considerable interest since local side reactions and vehicle components represent major 
safety concerns for vaccine formulations based on W/O emuls ions. For example, the 
prolonged presence of oil may induce necro-ulcerative les ions at the injection site [7). 
However, residues of mineral oil based emulsions at the injection site might be minimized 
by increasing the dispersibility of the emulsion. This may be accomplished by decreasing 
the dosage volume. Aim of the study was therefore to determine the impact of dosage-volume 
on efficacy of vaccines based on W/O emulsions in relation to local reactions caused by 
vaccine residues 
To this end, vaccines based on W/O emulsion, containing a combination of inactivated 
antigens of infectious bronchitis virus and Newcastle disease vi rus or only inactivated 
infectious bursa! virus OBDV) were administered int ramuscularly to 3 - 4 week-old chickens. 
While maintaining a constant amount of antigen we changed the dosage volume. Our results 
demonstrate that as a result the efficacy of antibody response was not significantly affected, 
but side effects at the site of injection were d rastically reduced . 
Materials and methods 
Preparation of vaccines 
A combination of Formalin-inactivated New Castle Disease Virus (N DV), strain Clone 30 and 
Infectious Bronchitis virus OBY), st rain Massachusetts 4 1 ,  both produced in eggs, were the 
vi ral avian antigens examined in one combination vaccine. 
Also a single vaccine containing Formalin-inactivated Infectious Bursa ! Disease Virus OBDV) 
strain D78 was examined. Vaccines fo r repeated injection were diluted with 0.01 M Phosphate 
buffer, pH 7.2 without addition of any immunopotentiating agent. 
Vaccine formulations tested we re saline formulations, which contained the vi rus suspension 
diluted with 0.01 M Phosphate buffe r, pH 7.2 and wate r-in-oil (W/O) emulsions. 
W/O emulsions were prepared using Mineral Oil (Marco! 52 from Exxon, USA) as oil phase. 
Tween 80 and Arlacel 80 (both Uniqema, UK) were used as surfactants in all the vaccines. 
The water-to-oil ratio of the emulsions tested was 60 % w/v aqueous phase and 40 % w/v 
oil phase .The W/O emulsion was prepared by adding the aqueous phase into the oil phase, 
while mixing was performed with high shear forces at 20.000 r.p.m. using the Ultra Turrax 
Type T25 OKA, Germany). The aqueous phase, containing the virus suspension and Tween 
80 was diluted with 0.0 1 M Phosphate buffer, pH 7.2. 
All emulsion were physically stable for at least 3 weeks at 37 ·c. 
Variation dosage-volume 
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All saline vaccines were prepared at a standard dosage-volume of 0,5 ml. 
NOV + IBV vaccines in W /0 emulsions were prepared at dosage-volumes of 0,5 ml and 0,2 5 ml. 
The total concentration of NOV + IBV virus suspension used in vaccine with a dosage-volume 
of 0,5 ml was 1 8, 1 96 w/v of the final vaccine. In vaccine with a dosage-volume of 0,25 ml 
36,2 96 w/v of the final vaccine of the NOV + IBV virus suspension was used. 
IBDV vaccines in W/0 emulsions were prepared at dosage-volumes of 1.0 ml, 0,5 ml, 
and 0.0 5 ml. All IBDV vaccines contained 100 units of IBDV per dose, irrespective of 
dosage-volume. 
Immunization of animals 
Groups of three-to-four week-old specific pathogen free (SPF) female White Leghorn chickens 
(n = 8 - 10) were vaccinated once in the breast muscle. Blood samples for serological tests 
were taken at 3, 6, 9 and 12 weeks after vaccination. Virus neutralization tests specific for 
IBDV were performed to determine the levels of antiviral serum antibody titers. 
During the course of the experiment all animals immunized with saline vaccines or emulsion 
vaccines appeared healthy without notable clinical symptoms. Local reactions at the 
injection site were monitored at 12 weeks after vaccination. 
All experiments were approved by an independent Animal Welfare and Ethical Review 
Committee. 
Assays for serum antibodies 
Serum levels of NOV-and IBV·specific antibodies were determined by a standard 
haemagglutination inhibition (HI) assay. Serial two-fold serum dilutions were prepared in 
96-well microtiter plates and mixed with an equal volume containing 8 heamagglutinating 
units/ 50 µI NOV or IBV antigen. 'Log titers were expressed as the reciprocal of the highest 
dilution that still resulted in complete inhibition of haemagglutination. Samples were 
considered positive at an inhibition of haemagglutination at dilutions 2: 1 :  2 (NOV) (2log2) 
and 1: 16 (IBV), respectively. 
Serum levels of IBDV· specific antibodies were determined by a virus neutralization 
assay. Serial two-fold serum dilutions were prepared in microtiter plates and mixed with 
an equal volume containing 650 TCIDSO / 100 µI of IBDV. After pre-incubation, Chicken 
Embryo Fibrolast (CEF) cells were added. The cells were cultivated for at least five days and 
then examined for the presence or absence of typical cytopathic effects. The titers of the 
test samples are expressed as means ('log) of the reciprocal of the highest dilution where 
all viruses are neutralized. 
Statistical analysis 
Comparison of means of serum titers was performed with one-way analysis of variance 
(ANOVA) by comparing two point values between groups and by group analysis between 
timepoints (GLM) with least significant difference (LSD) as multiple comparisons test. 
All results were generated using SAS (version 8.2) software. Differences were considered 
significant if P was less that 0.05. 




Results and discussion 
Effect of dosage volume on local site reactions 
Groups of three-to-four week-old specific pathogen free (SPF)  female White Leghorn 
chickens (n = 8 - 10) were vaccinated (0.5 ml/dose), in the breast muscle. Blood samples for 
serological tests were taken at weeks 3, 6, 9 and 1 2  a fter vaccination. Virus neutralization 
tests specific for IBDV were performed to determine the levels of antiviral serum antibody 
titers. 
During the course of the experiment all animals immunized with various emulsion vaccines 
appeared healthy without notable clinical symptoms. Local reactions at the injection site 
were monitored at 1 2  weeks after vaccination. 
vaccine Dosage volume number of animals out of l 0 
showi ng res idues of inoculum 
NDV + IBV in sa line 0.5 ml 0 
NDV + IBV in w/o emulsion 0.5 ml 8 
NDV + IBV in w/o emulsion 0.25 ml 7 
IBDV in saline 0.5 ml 0 
IBDV in w/o emu lsion  0.5 ml 8 
IBDV i n  w/o emulsion 50 µI 4 
IBDV in w/o emulsion l ml 9 
Table 1 : 
Local reaction score 1 2 weeks after vaccination. 
Effects of dosage-volume on specific antibody response 
Results of the immunizatio n  efficacies, measure d as serological responses of circulating 
virus-neutralizing antibo dy titers, are shown in figure 1 ,  2 and 3. 
As expected W/O based vaccines evoke higher antibody titers when compared to saline. 
Especially for the N DV + IBV combination vaccine the immunostimulating effect of the 
emuls ion results in a profound increase of serum antibody ti ters. 
Interesting ly, varia tion of dosage-volume di d not result in a significant difference of 
antibody response for both the NDV + IBV combination vaccine and the si ngle IBDV 
vaccine. 
Based o n  these data, we conclude tha t  the serological response triggered by the 
vaccine vehicles with identical antigen con tent, but suspende d an d a dminis tered at 
different vo lumes, does not depend on dosage-volume. 
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Serological responses (HI titres) of NDV 
6 9 1 2  
Weeks after vaccination 
• Saline, 
1 dose = 0.5 ml 
8 w/o emulsion, 
1 dose = 0.5 ml 
mu w/o emulsion, 
1 dose = 0.25 ml 
Serological responses (HI titres) of NDV 
Statistical analysis revealed no significant differences between the mean titres at each time point between 
the groups vaccinated with emulsion vaccines. 
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Serological responses (HI titres) of IBV 
• Saline, 
1 dose = 0.5 ml 
8 w/o emulsion, 
1 dose = 0.5 ml 
mu w/o emulsion, 
1 dose = 0.25 ml 
Statistical analysis revealed no significant differences between the mean titres at  each time point between 






Serological responses of IBDV-specific neutralizing antibody titres 
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Figure 3 :  
Serological responses o f  IBDV-speciftc neutralizing antibody titres 
Statistical analysis revealed no significant differences between the mean titres at each time point between 
the groups vaccinated with emulsion vaccines . 
In this s tudy we examined iden tical vaccine vehic les con taining the same amoun t of 
antigen per dose, which were adminis tered to chickens at variable dosage-volumes. 
Obviously, differences in dosage-volume also resul t in var iable an tigen c oncentrations. 
Th us in case of the IBDV vaccine, the formulation wi th a dosage-volume of I ml con tained 
an antigen concen trati on that was twenty-fold lower than that in the vaccine 
formulation of the 0.05 ml dosage-volume. Acc ordingly, the an tigen concen trations 
In these s amples were 100 U/ml and 2000 U/ml, respectively. Interestingly, this 
large difference in an tigen c oncentration did not resu l t  in a significan t difference in 
immunostimu lation as measured by serum an tibody ti ters specific for the an tigen. 
This phen omenon does not support a major influence of sus taine d release of the an­
tigens as a key feature underlying the known immunos timulati on of W /0 emulsions. 
Florence et al [8] described diffusi on and emulsion break down as two cri tical release 
mechanisms of W/0 emulsions. Since the W/0 emulsi ons used in the present work 
appeared  physically stable ,  as revealed by visual inspecti on, emulsion break down is 
less likely, implying that diffusi on probably represents the mechanism that c on trols 
the release of antigen. 
described diffusi on in Fick's Law :  
According t o  Fick 's law [9], represented by the formula 
J = - D M> / ox 
where: 
J is the diffusion flux in dimensions of [ (amount of subs tance) leng th-2 time- 1 1, 
D Is the diffusi on coefficien t, 
cJ> is the concen tration in dimensions of [ (amoun t of substance) length-') and 
x is the posi tion [length], 
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diffusion (J) is  l inearly related to the concentration (ct>). Hence, a change of concentration 
i nfluences diffu sion and therefore also the release profile of the vaccine-emulsion.  
Therefore, one would anticipate that in case of release of antigens from these vaccine 
emulsions,  the rateof release should have been influenced by the c hange of  concentration. 
Since no overt c hange in immune response was observed, even at  a twenty-fold c hange 
of concentration, the conclusion appears justified that the rate of release only plays 
a minor role, if any, in i mmunostimulation mediated by W/0 emulsions. In l ine with 
this conclusion are data from amputation experiments, which suggested that res ection 
of the injection site after 24 hours does not reduce i mmune responses ( 1  O]. The fact 
that a period of 24 hours of antigen residence may be sufficient to evoke an i ncrease 
of antibody production i s  also i n  l ine with data described by Itano et  al (1 l ]. In  this 
study two waves of translocation of antigens from the site of injection towards the 
local lymph node were revealed. Thus,  the first antigen influx appears to be derived 
from intact antigens that reach the T-cell zone in the lymph node early, i.e., within 0.5 
hours after injection. The second wave of antigen influx occurs within 24 hours after 
injection and stems from antigen-presenting dendritic cells at the injection s i te that 
contain processed antigen and move towards the nearest draining node by afferen t  
lymphatic vessels. 
Considering W/0 emulsions as a matrix system based on oil,  carrying dispersed water 
droplets containing antigens, it is possible that intact antigens within water d roplets 
present on the outside of this oil  matrix may relatively easily dissociate from the W/0 
vehicle. This fraction of antigen may thereby give rise to a first wave of antigen i nflux. 
However, antigens within water droplets i nside the oil  matrix will not or less readily 
be released, therefore requiring processing by APCs first, thus causing a se cond wave 
of antigen influx. 
I nterestingly, the first wave of antigen influx involves only a minute amount of intact 
antigen, since analysis of in-vitro release characteristics of W/0 emulsions showed 
no detectable antigen release during the first three weeks (12]. This lack of antigen 
release might be the result of low antigen concentration in the W/0 emulsion vehicle. 
Because of this low antigen concentration, the majority of the microspheral water 
droplets dispersed in the oil  may contain no antigen material. Theoretically these 
empty droplets might even block antigen release. 
As a result, an i ncrease of antigen concentration, by decreasing dosage-vo lume, may 
be possible, to a certain extent, without affecting delay of antigen release. 
Our data are in line with results of conceptually similar studies in Salmonids. Unpublished 
observations (A. Tangeraas, Intervet Norbio Bergen) showed that neither efficacy nor duration 
were affected by decrease of dosage volume from 0.2 ml to 0.1 ml, while on the other hand 
safety benefits. Especially for vaccines based on W/0 emulsions, a reduction of the dosage 
volume is a useful approach to minimize local reactions at the injection site without affecting 
efficacy. As a result these types of vaccine-vehicles with improved safety requirements may 
now become useful for human vaccines as well. 
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The purpose of the studies described in this thesis was to unravel the mechanism of action 
of W/O emulsions as efficacious vehicles of inactivated vaccines. In this final chapter we 
will summarize and critically discuss several of our findings. In addition, we will present 
some preliminary studies which may provide further insight into this mechanism and con­
sequently could be of help in guiding future directions of this work. 
Description of W/O emulsions as simple controlled release systems for antigens does not 
lead to satisfactory explanations for these findings. Apart from releasing antigens W/0 
emulsions might improve immune response rather by retaining antigen as a depot at the 
injection site. 
One aspect supporting the antigen retaining depot theory involves the improvement of 
stability of antigens, in particular for W/O emulsions based on inert Mineral Oil. In that case 
localization of antigens in W/O emulsions is important. An in depth determination of this 
localization warrants further work. 
Another mechanistic concept of Mineral Oil based W/O emulsions may include the attrac­
tion of appropriate APCs in order to improve uptake of antigen after endocytosis. Mineral 
oil may contain specific lipid mediators that increase the expression of costimulatory mol­
ecules on APCs to effectively initiate immune responses. Further investigations are neces­
sary to prove and unravel this concept. 
Discarding the idea of W/O emulsion as a controlled release system forms the basis for 
allowing these new concepts and therefore most attention is given to this aspect. Future 
studies are necessary to confirm the thought that vaccines based on W/O emulsions are not 
controllable release systems. Application of non-invasive in-vivo bio-imaging techniques to 
study release properties of delivery systems, using appropriate fluorescent tags attached 
to antigens and oil phase, might be suitable to confirm this concept and deserves more 
investigations. 
A mechanism not related to controlled release could result in reduction of the dosage 
volume of W/O emulsion-based vaccines without influencing serological responses. This 
would minimize local reactions and make this type of vaccine-vehicle even accessible for 
particular human vaccine programs. 
6.1 Release mechanism 
For decades, W/O emulsions have been described as slow release systems. Therefore, the 
primary goal was to obtain more insight as to the importance of a slow antigen release as 
a mechanism underlying the induction of antibody responses. 
Our results showed that a role for slow release in the production of W/O emulsions-based 
vaccines can be questioned. Studies on the kinetics of release as performed in vitro and 
described in chapter 2, did not reveal any release of antigens over a period of 1 2  weeks. 
In chapter 3 specially formulated W/O emulsion based on Miglyol 840 neither showed a 
significant release of antigen in vitro during 12 weeks. In addition, the same W/O 
formulation containing Mineral oil instead of Miglyol 840 did not show any detectable 
release over a period of 3 weeks. 
Lack of antigen release might be the result of a low antigen concentration when compared 






shear emuls ification contain a large amount of water droplets. The theoretical amount of 
droplets per ml of emulsion can be calcu lated: 
Most e mulsions tested contained 40 96 w/v (= v/v) of w ater phase, i.e., 0,4 ml of water 
phase per ml emulsion. 
High shear emulsification results in a d ispersed water phase with an average droplet 
s ize of 1 µm (= average d iameter of d ispersed water droplets). 
The equat ion of Volume (V) is: V = 4/3 TT r3 , w ith r = 0.5 µm = 0.5 . 10 • c m. 
The volume of one droplet of a d ispersed water phase is therefore: 
4/3 . 3.,14 . (0.5. 10 4)3 cm' (= ml) = 5,2 . 10-10 ml 
Per 1 ml of e mulsion containing 4. 10-1 ml of water phase, the amount of water 
droplets is therefore: 4. 10-1 / 5,2 . 10-10 = 7,7. 108 droplets. 
For example, the IBDV vaccine contains 1000 defined Ant igenic Units/ ml of ant igen 
material. Unpublished measurements showed that l 000 Ant igenic Units per ml corresponds 
to a minimum of 2. 108 virus particles per ml (E.Jagt, Intervet Internat ional Box meer). This 
means that approx imately only 30 96 of the water droplets of the emulsion may contain 
virus part icles and that ± 70 96 of the droplets are e mpty. Today the general consensus is 
that W/O e muls ions act as an antigen depot at the inject ion s ite, releasing only minute 
amounts of ant igen over t ime (signal 1). 
Interestingly, the study described in chapter 2 showed that an increase of the water-to-oil 
ratio in c onjunction with a high shear emulsification clearly inh ibits serological responses 
of Mineral oil based vaccines. This comb inat ion of an increase of water ratio and h igh 
shear emulsificat ion, results in a cons iderable increase of the amount of water droplets 
dispersed in the oil phase. Remarkably, serological responses of Miglyol based vaccines 
were not affected, but rather improved by increasing the w ater-to-oil rat io. 
As ment ioned before, these W/O emuls ions, relying on the use of Miglyol 840, also showed 
no detectable release of ant igen in vitro during 1 2  weeks, while the same W /0 formulation 
with Mineral o il neither showed any detectable release over a period of only 3 weeks. 
Together, these findings suggest that the ant ibody response tr iggered by W/O e mulsions 
with Mineral oil is accomplished by a mechanism that involves the release of minute 
amounts of ant igen, in conjunct ion w ith the maintenance of ant igen as a depot at the 
inject ion s ite. 
This conclusion would be in l ine w ith data reported by Itano et al [ l ]. These authors 
showed a two•step mechanism of translocat ion of antigens from the s ite of inject ion 
tow ards the l ocal lymph node. The first ant igen influx derives from the flow of intact 
ant igens that reaches the T-cell zone in the lymph node early after inject ion, i.e., w ith in 
30 minutes. The second wave of antigen influx occurs w ith in 24 hours after injection. This 
flow is mediated by ant igen-present ing dendrit ic cells, which orig inate from the inject ion 
s ite and c ontain processed antigen. These cells move towards the nearest draining node 
by afferent lymphat ic vessels. Th is mechanism would be in l ine w ith data from amputat ion 
experiments, which revealed that resect ion of the vaccine inject ion s ite after at least 24 
hours does n ot seem to reduce vaccine-induced immune responses [2]. 
When considering W/O e muls ions as an oil matrix carry ing d ispersed water droplets that 
contain ant igens, one readily imagines that intact antigens w ithin water droplets that 
local ize at the surface of th is oil matrix become more readily available to the environment 
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than those tha t  loca lize in the inner core of the oi l matrix. Hence, antigens released from 
the surface thus likely represent a firs t wave of an tigen influx. Since such availabili ty will 
be rela tively de layed for antigens released from the inner core, this fraction can time 
wise become susceptible to processing by APCs a t  the injec tion site, thereby reflec ting 
the second wave of antigen influx. The firs t wave of antigen influx involves only a minute 
amount of intact antigen, since analysis of in-vitro release characteris tics of W/0 
emulsions showed no de tectab le antigen release during the firs t three weeks as described 
in chapter 3. 
The concep t of a two-s tep mechanism of translocation also fi ts wi th the resul ts of the 
inves tigations of emulsion-based depot function, as described in chapter 4 of this thesis. 
In this s tudy s timulation of the an tibody forming cells, as a result of repeated daily 
injections of minute amounts of antigen, resulted in a less pronounced antibody titre 
when compared to one injection of a full dose, formula ted in a W/0 emulsion. Hence, i t  
i s  temp ting t o  sugges t that an antigen retaining depot a t  the injection site could be 
responsible for an improved antibody response. The prolonged avai labili ty of antigen 
wou ld thus favour humeral immune responses. 
6.Z In-vivo imaging of antigen release characteristics 
In the antigen release assays described in chap ter 2 and 3 vaccine formulations were mixed 
in isotonic 0.0 1 M phosphate buffer, pH 7.2, and placed a t  37 ·c while s tirring. One may 
question whe ther this sys tem represents a realis tic simulation of in-vivo conditions. The 
potential in fluence of degradation of oil or antigens on antigen release were disregarded 
since the buffer-based system did not contain biological components such as catabolic 
enzymes. Therefore, we searched for a method to measure antigen re lease properties of 
delivery systems in-vivo and considered the use of quantum dots for this purpose. Quantum 
dots are self-i lluminating particles. Their size ( 20 - 70 nm) is typically in the range of virus 
par ticles or subuni ts of large macro molecular antigens. Their optical characteris tics a llow 
sensi tive imaging in small animals. Emission of light can be identified at a tissue depth 
of several ems. Therefore, inves tiga tion of release and dis tribution characteris tics when 
formulated in distinct vaccine vehicles can be performed easily by monitoring these 
bi oluminescent quan tum dots as model for inac tiva ted antigens. This is a prac tica l 
non-invasive method, which may help to unders tand the spa tio-temporal release features of 
antigens in-vivo, when formulated in dis tinct delivery sys tems. 
We performed a preliminary study in mice vaccinated subcutaneously with quantum dots 
formulated ei ther in W/0 emulsions, 0/W emulsions or dilu ted in an aqueous buffer. At 
several time in tervals a fter vaccination the animals were anaes the tized and a whole body 
fluorescence image was obtained, using !V IS 100 equipment. Images obtained after various 
time in terva ls are shown in Fig. I .  In addition, as shown in figure 2, vi ta l  organs were 
analyzed after 60 days. 
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Figure 1 .  Typical whole body scans obtained with IVIS 1 00 equipment. Scans of Balb/c mice, injected with 
"Qtracker 705" quantum dots in: ( 1 )  0/W emulsion, 20 pmol/dose; (2) 0,01 m PBS buffer, 20 pmol/ 
dose; (3) W/0 emulsion, 20 pmol/dose; (4) W/0 emulsion, 2 pmol/dose. (5) represents a control 
animal that was not treated with quantum dots. 
Scans were taken at (A) 3 days, (B) 30 days and (C) 54 days, except for (S). W/0 and 0/W emulsions 
based on mineral oil (Marcol 52 from Exxon, USA), similar to the emulsions described in chapter 3 ,  
were formulated with quantum dots. These W/0 and 0/W emulsions were prepared with 0.2 % (w/v) 
Tween 80 (and 0.5 % (w/w) Arlacel Pl 3S (both Uniqema). The water-to-oil ratio of all emulsions was 
60 % (w/w) aqueous phase and 40 % (w/w) oil phase. The aqueous phase of the emulsion contained 
quantum dots. Quantum dots used were Qtracker 705 non-targeted Quantum dots (lnvitrogen-life 
technologies) with an emission max between 700 and 71 5 nm. Two W/0 emulsions were pre­
pared with different concentrations of quantum dots: 2 pmol/0.1 ml and 20 pmol/0. 1 ml. The 0/W 
emulsion prepared contained 20 pmol/0. 1 ml of quantum dots. Also a formulation of 20 pmol/0. 1 ml 
quantum dots in an aqueous 0.01 m PBS buffer was prepared. Balb/c mice were injected 
subcutaneously (in the back, right above the tail) with these quantum dots formulations, 0. 1 ml per 
dose. Per formulation one mouse was treated. As a reference, one mouse was treated with 0.01 m 
PBS buffer without quantum dots. Scanning was performed with IVIS 1 00 equipment using an IVIS 
1 76 camera. Time points of scanning after administration of the quantum dots were: 0, 3 days, 
30 days and 54 days. During scanning the mice were anaesthetized with isoflurane/oxygen. 
After final measurement the mice were sacrificed to determine the presence of Quantum dots in the 






















Figure 2. Analysis of Quantum dots in the vital organs (a) liver, (bl kidney, (cl spleen, (d) lymph node, (e) 
lungs anf (f) gall-bladder of mice 60 days after injection of "Qtracker 705" quantum dots in: ( 1 )  0/W 
emulsion, 20 pmol/dose; (2) 0,01 m PBS buffer, 20 pmol/dose; (3) W/0 emulsion, 20 pmol/dose; 
(4) W/0 emulsion, 2 pmol/dose. See also legend of Fig. l .  
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The results showed that quantum dots formulated in W/0 emulsion remained localized 
at the injection site as expected, whi le Quantum dots in an 0/W emulsion disappeared 
from the injection site with time. Remarkably, quantum dots in an aqueous PBS buffer also 
remained at the injection site, similar to the W/0 emulsion, during the first 3 days. In all 
animals, the intensity of the signal bleached over time. Organ analysis of the sacrificed 
animals in all groups, as done after 60 days, showed the presence of quantum dots in liver, 
sp leen, kidneys and bile. 
The results showed that quantum dots formulated in W/0 emulsion remained localized 
at the injection site as expected, while Quantum dots in an 0/W emulsion disappeared 
from the injection site with time. Remarkably, quantum dots in an aqueous PBS buffer also 
remained at the injection site, similar to the W/0 emulsion, during the first 3 days. In all 
animals, the intensity of the signal bleached over time. Organ analysis of the sacrificed 
animals in al l groups, as done after 60 days, showed the presence of quantum dots in liver, 
spleen, kidneys and bile. 
This pilot bioluminescence study shou ld be regarded as an exp lorative investigation, which 
as yet does not justify any firm conclusions. However, the primary goal of this study was 
to obtain a better understanding of the kinetics of antigen processing within the emulsions 
after in vivo adminstration. In that context, we suggest that the current approach justifies 
a further detai led study and that bioluminescence represents an excellent tool for 
studying vaccine behaviour in-vivo. However, we consider Q tracker 705 quantum dots 
not the most suitab le traceable representatives for antigens. Fluorescent tags attached to 
antigen material might be more suitable. Hence, fluorescense imaging would therefore be 
more promising. In addition, the use of lipid probes would also make it possible to 
investigate simultaneously the behaviour of the oil phase of vaccine formulations in-vivo. 
This will be a topic of future research. 
Uptake of antigen by APC's after endocytosis 
In chapter 3 we studied the efficacy of vaccine formulations based on W /0, 0/W and W/0/W 
emulsions that were composed of identical ingredients in identical amounts. In general, 
the immuno-potentiating effect of W/0 was superior to that of 0/W or W/0/W. For W/0 
emulsions these results show an inverse relationship between the height of the in-vivo 
antibody responses and antigen release levels measured in-vitro. By contrast, in case of an 
0/W emulsion, a high antigen release in-vitro evoked humoral responses in-vivo that were 
inferior to those triggered by W/0-antigen formu lations. 
Desorption of the antigen into interstitial fluid may not be the critical feature for W/0 
emulsions to act as immuno-potentiators for antigen-specific T-ce ll help. However, since 
initiation of adaptive immune responses takes place in lymphoid organs, antigens need to 
be trans located from the site of injection towards the local lymph node or the spleen, where 
interaction with adaptive T cells and B ce lls allows the comp letion of T-cell-dependent 
B-cell responses [3). Mineral oil present at the injection site may play an important role in 
attracting appropriate APCs to eventually provide signal 1 in the lymph node. Instead of 






after endocytosis of antigen-containing (water-in)-oil fragments by these recruited and/or 
local APCs. An increase of viscosity may hamper this process for mineral oil based 
emulsions, leading to less immuno-availability of antigen in the draining lymph node as 
shown in our study described in chapter 2. After uptake and processing of the antigens in 
this manner, the APCs presumably transport the antigens to the lymph node, where upon 
arrival they can prime naive antigen-specific T cells. 
However, the importance of a depot with stable antigens at the injection site should not 
be underestimated. As soon as antigen-specific antibodies have been formed, the sustained 
presence of antigen in draining lymphoid organ and at the injection site is l ikely to be an 
important factor for the persistence of the response. However, amputation of the injection 
sites performed 24 hours or later after immunization showed little, if any, reduction of the 
persistence of immune responses [2]. Hence, prolonged localization of the antigens at the 
injection site, even for only 24 hours, might be the main advantage of the W/O type 
emulsion compared to O/W or W/O/W types, which show no or negligible prolonged 
localization. 
6.4 Localisation of antigens in the W /0 emulsion 
All W/O emulsions of the study described in chapter 2 showed no detectable antigen release 
in-vitro over a period of 1 2  weeks. These series of W /0 emulsions included a mineral oil  
based emulsion with a water-to-oil ratio of 60 % (w/w) aqueous phase and 40 % (w/w) oil  
phase. A similar mineral oil based W/O emulsion is described in chapter 3 .  However, the 
emulsion described in chapter 3 showed detectable antigen release in-vitro after a period of 
3 weeks instead of 1 2  weeks. The main difference between the M ineral oil based W/O 
emulsions referred to in chapter 2 and chapter 3 is the composition of the surfactant. 
Besides the presence of 0.2 % (w/v) Tween 80 the Mineral oil based emulsion of chapter 3 
contained much less Ar lac el P l  35, i .e. 0.5 % (w/w) instead of 3 %. Ar lace I P l  35 is a 
polymeric surfactant with strong hydrophobic features. This surfactant located at the 
interface between water and oil may act as a coating if present in large amount. This may 
trap the antigens in the dispersed water phase hampering their release. Moreover, a large 
amount of polymeric surfactant may also avoid migration of the antigens from the water 
phase into the oil phase. 
Localisation of the antigen in a medium composed of saturated non-branched hydrocarbon 
chains, as found in mineral oil, could favour stability of antigens and may also directly be 
involved in improving the immune response. The absence of reactive groups in mineral oil 
may protect antigens from denaturation when interacting with the oil phase. Zelisko et al. 
showed that proteins residing at the interface of inert silicone oil emulsions are stabilized 
against denaturation [4). In addition, such an oil  phase may constitute a barrier to enzymatic 
attack and phagocytotic processing, thereby further protecting antigens. The early local 
reaction scores at 48 h observed for (metabolically) Miglyol-based emulsions as described 
in chapter 2 demonstrate that an initial, vigorous influx of leucocytes is not predictive for 
high antibody responses, because these non-priming phagocytotic cells may also cause a 
fast removal of antigens resulting in impaired immune deduction. 
Furthermore, migration of antigen to the oil phase supports the concept of W/O emulsions 
acting as an antigen-retaining depot at the injection site instead of an antigen releasing 
vehicle, which is also supported by work described in  chapter 5.  Located in or at the interface 
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of  the mineral oil phase, antigens are less likely to be removed from the injection si te, since 
the oil phase will be less easily removed. 
Migration to the oil phase may likely occur in case of hydrophobic antigens, such as 
those from enve loped  virus particles. Preliminary work (T. Jansen, M. Theelen, ln tervet 
In terna tional Boxmeer) showed that use of high shear forces during the emulsifica tion 
process may drive hydrophobic bacteria l antigens in to the continuous phase of the W/0 
emulsion, a phenomenon that can be observed microscopically. Application of high shear 
forces reduces the size of the water droplets, and bacterial ce lls may not fi t in these small 
droplets. By contras t, an emulsification process tha t  re lies on a relatively low shear force 
may keep the bacterial antigens in the larger water droplets. 
Light microscopic observation of bacteria is feasible, but not of virus particles, like IBV, 
NOV or IBOV, which have a size of about 60 - 100 nm. Hence observation of viral particles, 
localised in a W/0 emulsion, can only be achieved by electronmicroscopic examination. 
A preliminary a ttempt was made to do so using mineral oil based W/0 emulsions tha t  
contained IBV, N OV and IBOV, as  described in  chapter 3. The emulsion samples were 
nega tively s tained on fresh Carbon-films and on 300 mesh grids using 2 % Methyl Amine 
Tungstate. Magnifications of 17.500, 93.000 and 135.000 were s tudied. Unfortunately, no 
virus particles were detected (see Figure 3 and 4). Probably the samples were to thick and 
cloudy. Moreover, on ly a limited number of these virus particles are mixed in the emulsion, 
as described above, which frus trates visualization. 
Figure 3. 
Electron microscope observation of 
mineral oil based W/0 emulsion 
containing IBV, NDV and IBDV at 
magnification of 1 7.500. 
Figure 4. 
Electron microscope observation of 
mineral oil based W/0 emulsion 
containing IBV, NDV and IBDV at 





Figure 5 .  
Electron microscope observation of IBV (A), NDV (B) and IBDV (C) at  magnification s imilar to Figure 4 
(Source: 
Stewart McNulty of the Queens University, Belfast, see website http://www.ncbi .nlm.nlh.gov/lCTVdb/lmages). 
6.5 A�uvant features of mineral oil 
Factors that ex plain why mineral oil-based emulsions show higher antibody responses when 
compared to emulsions based on metabolizab le oil ,  l ike Miglyol 840, include prolonged 
stability of the antigen material and slow removal of antigens by non-priming phagocytotic 
cells because of the non-biodegradab ility of mineral oil. The lower efficacy of Miglyol-containing 
vaccines may also result from different st imu lation of APCs by Mig lyol type relative to 
mineral oil. Mineral oil possibly contains lipid substances that may act as immuno·stimulatory 
ligands, able to a lert the immune system. Of note, Dresser showed immuno-potentiation 
for an otherwise poorly immunogenic intravenously injected soluble protein by a Freund's 
adjuvant formulation, made up without antigen, when the emulsion was given at a distant 
subcutaneous site [5). The sensors for these l igands have not been defined. 
Recent ly, Sokolovska et al. [7] showed that alumin ium-containing adjuvants, which are T"2 
humoral immune response enhancers, increase the expression of CD86 on DCs, thereby 
stimulating release of lL-1 � and lL- 18 via caspase- 1 activation [7]. Hence, Mineral oil may 
contain com parable components that increase the expression of costimulatory molecules 
on A PCs to e ffectively initiate immune responses and influence the ability to direct T11 1 and 
T112 responses. 
Shaw et al. described that saturated straight -chained hydrocarbons of C- 15 to C-20 represent 
adjuvant features that are characteristic for Mineral oil when compared to biodegradable 
oils, which largely contain unsaturated chains [6]. However, possible APC act ivating effects, 
potentia lly linked to these specific lipid mediators present in mineral oil, have never been 
studied and merit further inves tigations. 
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Water-in-oil (W/0) emulsions are known as most effective adjuvants to generate high and 
durable antibody responses to vaccine antigens, following a single immunization. Oil-based 
emulsions are well-known immunopotentiators for inactivated, "killed" vaccines and are 
routinely used in many poultry vaccines, but also for pigs, fish, and ruminant. However, 
their structural requirements, presumably instrumental in producing the highest antibody 
titers, remain poorly understood. 
In chapter 2 the significance of certain pharmaceutical characteristics, including water/oil  
ratios, · ranging from 60/40 to 3 0/70 (% w/w) ·, droplet s i ze and type of oi l ,  i .e .  
non-metabolizable (Mineral Oil )  versus metabolizable (Miglyol 840) oil were investigated. 
Stabilization of emulsions was accomplished by the use of a polymeric emulsifier. Distinct 
W/0 emulsions were formulated with inactivated (i) Infectious Bronchitis virus (ilBV) and 
Newcastle Disease virus (iNDV), and evaluated in immunized chickens for magnitude and 
duration of in vivo antiviral antibody formation and local reactions. A high Mineral oil 
content proved most effective in causing an antibody response. In general, a larger 
droplet size evoked higher antibody responses for both oil types. lnoculum residues proved 
lower when using biodegradable Miglyol, compared to Mineral Oil, for all emulsion variants. 
Espec ially water-to-oil ratio and droplet size appear to provide useful parameters for 
improving (antiviral) antibody production by W/0 emulsions. 
In chapter 3 the relationship between emulsion structure and levels of in vivo antibody 
formation to iNDV and ilBV antigens, in 3 week-old chickens were investigated. The use of a 
polymeric emulsifier allowed for direct comparison of three types of emulsions, i.e., 
water-in-oil (W/0), oil-in water (0/W) and W/0-in water (W/0/W), while maintaining an 
identical content of components for each vehicle. The various formulations were prepared 
with either non-metabolizable Mineral Oil or metabolizable Miglyol 840. In addition, we 
assessed the inherent release capacity of each emulsion variant in vitro. In general, Mineral 
Oil vaccines showed superior efficacy compared to M iglyol 840-based vaccines. 
Remarkably, we noted that W/0 type emulsions induced the best immune responses, while 
they released almost no antigen during twelve weeks. 
The release requirements for vaccine antigens del ivered by adjuvants with presumed depot 
function like W/0 emulsions, are still unknown. W/0 emulsions are routinely used in the 
preparation of many poultry vaccines. They strongly activate antibody production, and are 
regarded as a depot from which antigens are slowly released, resulting in prolonged antigen 
residence time. However, from earlier studies it  was concluded that W/0 adjuvant activity 
is partly based on the immunostimulatory activity of the oil phase. In chapter 4 the dose 
and regimen requirements for viral antigen were assessed in immunization experiments 
in chickens. Three-to-four week-old White Leghorn chickens were repeatedly injected with 
inactivated antigen of infectious bursa! disease virus (iIBDV) during 48 days. Our aim was to 
compare the antibody responses in repeatedly injected animals, receiving fractioned doses 
of antigen, to the responses in animals receiving only one injection of the full dose of Ag, 
formulated in either a W/0 emulsion or in saline. We observed that repeated administration 
of small amounts of Ag results in a gradual increase of specific humoral immune responses 
during the i mmunization regimen. Immunization with a higher first dose evoked an early 
Summary 99 
higher antibody response, which however, reached a similar plateau level at the end of the 
regimen. When compared to lower first dose regimens a slow decline of serum antibody 
titer following two weeks after arrest of Ag injections indicated that repeated injection of 
small doses of Ag indeed mimics the efficacy of depot-forming adjuvants. All regimens of 
fractioned antigen in saline, however, proved less effective, when compared to a single dose 
vaccination of the cumulative amount of antigen formulated in a W/0 emulsion. From our 
data we conclude that W/0 emulsions are very effective vaccine vehicles for improving 
antigen-specific humoral responses in chickens, which relies on a combination of antigen 
residence-prolonging activity and direct immune stimulation. 
In order to find a method to study antigen release properties of delivery systems in-vivo, 
bio-imaging was performed in mice by monitoring the fate of (fluorescent) quantum dots as 
model for inactivated antigens. Although our explorative investigation described in Chapter 
6 did not yet lead to clear-cut concluding results, our preliminary data indicate that this 
practical non-invasive method may help to understand the spatio-temporal release of 
antigens in-vivo. The application of fluorescence imaging using more appropriate fluorescent 
tags attached to antigens and oil phase merits further investigations. 
For W/0 emulsions local side reactions and residues represent major safety concerns 
for these vaccine formulations. In chapter 5 we examined the effect of dosage-volume on 
efficacy and safety of vaccines, based on W/0 emulsions. Minimizing dosage volume might 
possibly minimize local reactions at the injection site, which would improve the prospects 
for W/0 emulsions as vehicles for vaccines requiring high safety profile. Mineral oil-based 
W/0 vaccines, containing a combination of inactivated antigens of IBV and NOV were 
administered intramuscularly to 3 - 4 week-old chickens with dosage-volumes of 0.5 ml or 
0.2 5 ml, both containing the same amount of antigen. Also the efficacy and safety of 
infectious bursa! disease vaccines, at 100 units per dose in W/0 emulsions, were examined 
in chickens at dosage-volumes of 1 .0 ml, 0.5 ml, and 0.05 ml. 
Our results reveal that the range of dosage volumes tested did not significantly influence 
the serological responses for all types of antigens studied. However, decreasing the dosage 
volume appeared to minimize local reaction scores. Hence, minimizing the dosage-volume 
of W/0 based emulsion vaccines might make this type of vaccine-vehicle even accessible 














Vaccins, hoe bet zit, en er was eens,_ 
Vaccins zijn middelen, die het afweersysteem van het lichaam (= immuun­
systeem) aanzetten tot het opbouwen van bescherming tegen bepaalde 
ziektes. Het vaccineren is een soort verdedigingsstrategie, dat het 
immuunsysteem helpt in  de altijd durende strijd tegen binnenvallende 
ziektekiemen. Daarom kan dit onderzoek over vaccins heel goed uitgelegd 
worden in de vorm van een spannend oorlogsverhaal met metaforen, die 
in de toegevoegde kaders verklaard worden (zie nummering). 
In de vroege middeleeuwen bevond zich een eilandengroep ( I )  in de 
grote wijde oceaan. Elk eiland (2) had een kustlijn bestaande uit hoge 
kliffen (3) en een netwerk aan riviertjes (4), waaraan stadjes lagen met 
tevreden en gelukkige bewoners. 
Echter een van de grootste gevaren, die voor deze eilanden dreigden, 
waren de Vikingen (5). Deze woeste zeelieden lieten zich niet afschrikken 
door de hoge kliffen, maar drongen ongezien met hun schepen de 
riviertjes van de eilanden binnen en verwoesten de steden. Aanvankelijk 
weerden de eilandbewoners zich door de schepen van de Vikingen te 
bekogelen met alles wat los en vast zat: rotsblokken, boomstammen enz. 
(6) Dit was meestal niet voldoende. 
Om te overleven werd derhalve op de eilanden een gilde (7) in  het 
!even geroepen die gespecialiseerd was in het opbouwen van een 
verdedigingssysteem. Deze gilde ontwikkelde de techniek om een veelvoud 
aan vallen (8) te bouwen van een vlechtwerk van hout. Deze vallen werden 
in de rivieren geplaatst, daar waar de Vikingen met hun schepen voeren. 
Als een schip in die val voer, zat het vast en was het uitgeschakeld. 
Omdat deze houten vallen een beperkte houdbaarheid hadden en voort­
durende vervanging een gehele ontbossing van het eiland zou betekenen, 
werden de vallen alleen gebouwd, als er signalen binnengedrongen dat er 
Vikingen waren. Bewakers (9)  werden opgesteld langs de kust en rondom 
de rivieroevers. Zij controleerden het aangespoelde rivierslib op vreem­
de niet inheemse voorwerpen. Als de bewakers voorwerpen vonden, die 
ze herkenden als afkomstig van de Vikingen, bijvoorbeeld een peddel 
met Vikingmotieven ( 1 0), dan werden die in een speciale korf gedaan 
en rechtsreeks naar de gildenhuizen ( 1 2 )  gebracht, die gebouwd waren 
op het eiland. In die gildenhuizen bevonden zich de meesters ( 1 1 )  van 
het verdedigingssysteem, die alle kenmerken van Vikingen herkenden. 
De bewakers toonden aan deze gildenmeesters de door hen gevonden 
Vikingse voorwerpen. De meesters waren echter pas overtuigd dat dit  be­
wijzen waren van de feitelijke aanwezigheid van Vikingen in hun binnen­
wateren als er ook vers aangespoeld rivierslib ( 1 3) aan deze voorwerpen 
plakte. Was dit het geval, gingen de gildenmeesters over tot actie en 
rekruteerden een grote hoeveelheid aspirantleden ( 1 4). Deze leden 
kregen alien een stoomcursus hoe de houten Vikingvallen gebouwd en 
(1 ). Groep van gewervelde 
dieren. 
(2): Het /iehaam van elk 
individueel dier / kip. 
(3): De huid, het grootste 
orgaan van het 
immuunsysteem. 
(4): 8/oedvaten. 
(5): £en speeifiek ziektekiem 
(kan virus of baeterie zijn). 
(6): Aangeboren 
immuunsysteem, 
niet speei{iek gerieht tegen 
een bepaalde ziektekiem. 
(7)· Verworven 
immuunsysteem, we/ 
speeifiek gerieht tegen 
bepaalde ziektekiemen. 
(8): Antistoffen tegen 
bepaalde ziektekiemen. 
(9): APCs = Antigeenpresen-
terende eel/en = eel/en van het 
immuunsysteem, die als taak 
hebben 'herkenbare de/en van 
het ziektekiem' 
(• (10): Antigeen) op te nemen 
& te presenteren aan 'eel/en 
van het immuunsysteem, die 
antigenen herkennen' 
<� (1 1): T-eellen). 
(12): Organen van het 
speeifiek immuunsysteem, 
zoals /ymfeknopen, thymus, 
milt of bursa. 
( 13): £en extra signaa/ van 
APCs, dat naast het antigeen 
nodig is om T-eel/en te 
aetiveren (= Co-stimulatle). 
(14): Cellen van het 
immuunsysteem, die 
speeifieke antistoffen kunnen 
produeeren (= 8-eel/en). 
Vaccins, hoe het zit, en er was eens... 10 1 
geplaatst moesten warden. Deze aspirantleden verlieten de gildenhuizen 
als volwaardige leden (1 5) en voeren direct de rivieren op om aldaar 
vallen te maken en te plaatsen. Dit verdedigingssysteem werkte goed, 
maar toch kon helaas niet altijd warden voorkomen, dat de Vikingen er 
in slaagden enkele steden te beschadigen, voordat ze werden tegenge­
houden. 
Nu bevond er zich midden in deze eilandengroep een groat eiland, dat 
geheel anders van vorm was ( 16): dit eiland bestond namelijk uit een 
hele hoge berg, waardoor het vrijwel onneembaar was voor de Vikingen. 
De bewoners van dit bergeiland leken in sommige opzichten enigszins 
op die van de omringende eilanden, maar waren verder ontwikkeld en 
bezaten enkele technische vernuften. Zo beschikten ze over verrekijkers 
( 17), waarmee ze alle activiteiten van de rondliggende eilanden konden 
bestuderen. Dankzij deze verrekijkers kenden de bergbewoners het 
verdedigingssysteem van de eilanden. Ze wisten oak, dat voordat het 
verdedigingswerk in stelling gebracht was er toch nag altijd enkele 
steden op de eilanden door de Vikingen vernietigd werden. Oak 
konden de bergbewoners zien, wanneer de Vikingen op komst waren. 
Dus besloten ze voortaan het verdedigingsysteem van omringende 
eilandgroepen vroegtijdig tot actie aan te zetten, nag voordat de Vikingen 
arriveerden. Dit deden de bergbewoners door typisch Vikingse 
attributen, die zij skolls noemden op de eilanden te plaatsen met de 
bedoeling, dat bewakers van de eilanden het zouden oppikken. 5kolls 
waren schedels van dode Vikingen ( 1 8), waarvan het bovenstuk 
afgezaagd was. De Vikingen gebruikten deze skolls als drinkbeker. Het 
vinden van skolls op hun eiland zouden de bewakers zeker zien als 
teken van aanwezigheid van Vikingen. 
Ondanks de ontoegankelijkheid van de eilanden door de steile kliffen 
hadden de bergbewoners reeds een systeem ontwikkeld om de skolls 
op de eilanden te krijgen: zij maakten gebruik van grate katapulten ( 19), 
die de skolls over de hoge kliffen konden schieten. Om de skolls 
geschikt te maken als katapultkogel, werden ze gemengd in een smeer­
olie met wat water (20). Door de eilanden op deze wijze te beschieten 
(21) bl eek wonderwel te werken als effectief verdedigingsmiddel. Zadra 
de bergbewoners de komst van Vikingen in de verte zagen, werden de 
omliggende eilanden beschoten met dit mengsel van smeerolie en skolls. 
Bij aankomst van de Vikingen waren alle verdedigingswerken in stelling 
gebracht en de Vikingen konden weinig uitrichten. Helaas had het 
beschieten van de eilanden met dit smeeroliemengsel wel een nadeel. 
De vele beschietingen zorgden voor milieuverontreiniging: de smeerolie 
bleef liggen en daardoor werden flora en fauna plaatselijk beschadigd 
(22). De bergbewoners wisten dit en hadden geprobeerd de smeerolie 
te vervangen door water, maar dat zette het verdedigingssysteem op de 
eilanden niet aan tot actie. 
(15): Aangepaste B-ce/, die anti­
stoffen produceert specifiek 
tegen bepaald antigeen. 
I (J 6): De mens. 
(1 7): Technieken om 
/ichamelijk onderzoek te 
plegen, zoals het nemen van 
b/oedmonsters. 
(I B): Een afgedood ziekte­
kiem, dat kan functioneren 
als antigeen in een vaccin. 
(19): Een injectie, die met een 
spuit ingebracht wordt. 
(20): Water gemengd in 
Minerale o/ie. Dit wordt een 
emulsie genoemd (vergelijk 
met Mayonaise). Ats deze 
dun genoeg is, kan het als 
injectievloeistof van een 
vaccin gebruikt warden. 
(21): De vaccinatie. 
(22): Minerale o/ie kan niet 
door het /ichaam afgebro­
ken en laat dus onwense­
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De bergbewoners snapten niet hoe dit in elkaar zat en stelden derhalve 
een onderzoeker (23) aan. Deze zocht een groep eilandjes (24) uit, waarvan 
hij de riviertjes met een verrekijker goed kon bestuderen op de 
aanwezigheid van Vikingvallen (25). Hij bestookte deze eilanden met 
skolls gebruik makend van de katapulten. Hij bemerkte inderdaad dat 
een grote hoeveelheid Vikingvallen in de riviertjes te zien waren, 
wanneer de eilanden bestookt werden met skolls gemengd in smeer­
olie met water. Hij bedacht dat de skolls langzaam uit de smeerolie 
vrijkwamen (26), en dus over een langere periode door de bewakers 
gevonden konden worden. Hierdoor bleven de gildehuizen !anger 
doorgaan met het opleiden van vallenmakers. Hij trachtte dit idee te 
bevestigen door over een Iangere periode een eiland te beschieten met 
kleine hoeveelheden aan skolls gemengd in water. Hij zag inderdaad dat 
de hoeveelheid Vikingvallen in de riviertjes toenam, zolang hij het eiland 
maar bleef bestoken met deze kleine hoeveelheden. Echter het aantal 
Vikingvallen in de riviertjes was veel minder dan wanneer een 
beschieting had plaatsgevonden met skolls in smeeroliemengsel. 
Ook probeerde hij een mengsel van skolls in levertraan (27) met wat 
water en torpedeerde hiermee een ander eiland. De Ievertraan trok 
allerlei vogels en dieren, zoals honden aan, die de skolls gedipt in  de 
levertraan beschouwden als lekkernij en er mee vandoor gingen. Het 
resultaat was dat er weliswaar geen olie bleef liggen, maar ook dat er 
maar enkele nieuwe gildenleden aangezet waren tot het maken van 
Vikingvallen. Wellicht waren de meeste skolls al weg voordat de bewakers 
kwamen. Smeerolie was dus duidelijk anders dan levertraan: smeerolie 
bleef liggen. Een test met een veel kleinere hoeveelheid smeeroliemengsel 
met een gelijke hoeveelheid skolls bleek ook goed te werken en gaf veel 
minder milieuverontreiniging. 
Deonderzoeker had nu een nieuwe theorie: de skolls in smeerolie-met-water 
mengsel komen niet zozeer langzaam vrij, maar het mengsel trekt 
de aandacht van de bewakers. De smeerolie gemengd met water lijkt 
namelijk wel wat op het rivierslib, waar de bewakers gewoon zijn om naar 
vreemde voorwerpen te zoeken. Eenmaal bij het smeeroliemengsel 
aangekomen, zullen de bewakers altijd skolls aantreffen, omdat deze 
daarin vastgeplakt zitten. Misschien dat de gildenmeesters de aan de 
skolls geplakte smeerolie wel voor verse rivierslib aanzagen (28) en 
daarom tot actie overgingen. De onderzoeker deed verslag (29) aan de 
bergbewoners en stelde voor zijn theorie te toetsen door in de skolls 
waxinelichtjes (30) te plaatsen. Hierdoor is het wellicht mogelijk het lot 
van de skolls met de verrekijker te volgen nadat ze op de eilanden 
terecht zijn gekomen na de beschieting. Op die manier zou dan de 
nieuwe theorie kunnen warden bevestigd en dat zou misschien een 




(25): Het nemen van bloed-
monsters, waarvan in de 
sera de aanwezigheid van 
antisto{fen bepaald wordt. 
I (26): Controlled release. 
(27): Een o/ie, die door het 
/ichaam a(gebroken kan 
warden. 
(28): Misschien dat emulsies 
op basis van Minerale o/ie 
APCs aanzet tot het geven 
van een extra signaal aan 
T-cellen (co-stimulatie), iets 
wat andere o/ien minder of 
niet doen. 
(29): Dit boekje. 
(30): Een label plakken aan 
het a(gedode ziektekiem I 
antigeen, dat in het /ichaam 
van het dier zichtbaar 
gemaakt kan worden zonder 
in te grijpen in het /ichaam 
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ANTIGEEN 
WATER·IN·OLIE EMULSIE 
Figure 1. Schematische weergave van een mechanisme, waarbij water-in-olie emulsies een rol kunnen spelen 
bij de antigeenopname door antigeen presenterende cellen en de aanmaak van antistoffen. 
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